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ABSTRACT
Adult bronchial asthma (hereinafter, asthma) is characterized by chronic airway inflammation, reversible airway
narrowing, and airway hyperresponsiveness. Long-standing asthma induces airway remodeling to cause in-
tractable asthma. The number of patients with asthma has increased, and that of patients who die from asthma
has decreased (1.5 per 100,000 patients in 2012). The aim of asthma treatment is to enable patients with
asthma to lead a normal life without any symptoms. A good relationship between physicians and patients is in-
dispensable for appropriate treatment. Long-term management with antiasthmatic agents and elimination of the
causes and risk factors of asthma are fundamental to its treatment. Four steps in pharmacotherapy differentiate
between mild and intensive treatments; each step includes an appropriate daily dose of an inhaled corticoster-
oid, varying from low to high. Long-acting β2-agonists, leukotriene receptor antagonists, and sustained-release
theophylline are recommended as concomitant drugs, while anti-immunoglobulin E antibody therapy has been
recently developed for the most severe and persistent asthma involving allergic reactions. Inhaled β2-agonists,
aminophylline, corticosteroids, adrenaline, oxygen therapy, and others are used as needed in acute exacerba-
tions by choosing treatment steps for asthma exacerbations depending on the severity of attacks. Allergic rhini-
tis, chronic obstructive pulmonary disease, aspirin-induced asthma, pregnancy, asthma in athletes, and cough-
variant asthma are also important issues that need to be considered.
KEY WORDS
diagnosis of adult asthma, epidemiology of asthma, long-term management, management of acute exacerba-
tions, specific considerations
1. Aim of the Management, Definition,
Type, Diagnosis, and Severity of Asthma
1.1. Definition and Pathophysiology of Asthma
Adult bronchial asthma (hereinafter, asthma) is char-
acterized by repetitive cough, wheezing, dyspnea, re-
versible airflow limitation, and airway hyperrespon-
siveness. Asthma symptoms tend to be more severe
in more hyperresponsive airways, but airway hyperre-
sponsiveness is not always associated with asthma
symptoms. Pathological findings in asthma include
chronic airway inflammation accompanied by the in-
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Table　1　Aims of asthma treatment
1. To lead a normal and healthy life, and maintain normal growth.
2. To maintain normal respiratory function:
Peak expiratory fl ow (PEF) variation, <20% of the predicted value;
PEF, ≥80% of the predicted value.
3. To ensure sufficient night sleep without cough or dyspnea at night or in the early morning.
4. To prevent asthma attacks.
5. To prevent death from asthma.
6. To prevent adverse effects caused by therapeutic agents.
7. To prevent the development of irreversible airway remodeling.
Table　2　
1. Upper respiratory tract diseases: laryngitis, epiglottitis, vocal cord dysfunction 
2. Proximal respiratory tract diseases: endotracheal tumor, foreign body aspiration, tracheomalacia, endobronchial tuberculosis,
sarcoidosis
3. 
4. Cardiovascular diseases: congestive heart failure, pulmonary thromboembolism
5. 
6. Other causes: spontaneous pneumothorax, vagotonic effects, hyperventilation syndrome, and psychogenic cough
7. Allergic respiratory diseases: allergic bronchopulmonary mycosis, eosinophilic granulomatosis with polyangiitis (EGPA) 
(allergic granulomatous angiitis, Churg-Strauss syndrome), eosinophilic pneumonia
Differential diagnosis for asthma
Diseases of the bronchus and alveolar regions: chronic obstructive pulmonary disease, diffuse panbronchiolitis, pulmonary 
fibrosis, hypersensitivity pneumonitis
Cough induced by medicines, such as angiotensin-converting enzyme inhibitors
Table　3　Diagnosis of adult asthma: key features
1. Recurrence of paroxysmal dyspnea, wheezing, and cough (particularly at night and in the early morning)
2. Reversible airfl ow limitation: improvement with time or treatment. Diurnal variation in the peak expiratory fl ow rate, ≥20%. 
Forced expiratory volume in one second increased by ≥12% and ≥200 mL of the absolute volume by β2-agonist inhalation
3. Airway hyperresponsiveness: increased airway contractility to acetylcholine, histamine, or methacholine
4. Atopy: IgE antibodies against environmental allergens
5. Airway infl ammation: increased levels of eosinophils and ECP in sputum and peripheral blood, Creola bodies; increased frac-
tion of exhaled nitric oxide
6. Differential diagnosis: exclude other cardiopulmonary diseases
ECP, eosinophil cationic protein.
filtration of proinflammatory cells such as eosino-
phils, lymphocytes, mast cells, and others, and by the
detachment of the airway epithelial cells.1,2 While
many patients have immunoglobulin E (IgE) antibod-
ies against environmental allergens, airway inflamma-
tion and lymphocyte activation are noted even in pa-
tients without allergen-specific IgE antibodies. The
etiology of asthma is multifactorial, and its clinical
picture varies greatly among patients; thus, different
clinical pictures of asthma have attracted attention.
Some patients show airway inflammation with pre-
dominating neutrophils. Patients with long-standing
asthma show airway remodeling, involving subepithe-
lial fibrosis under the basement membrane, smooth
muscle hypertrophy, and submucosal gland hyperpla-
sia, which results in intractable asthma with irrevers-
ible airflow limitation and persistent airway hyperre-
sponsiveness.3
1.2. Aim of the Management and Treatment of
Asthma (Table 1)
The aim of the management and treatment of asthma
is to alleviate airway hyperresponsiveness and airflow
limitation by eliminating the inducers of airway in-
flammation and airflow limitation, by using pharmaco-
therapy to suppress inflammation, and by dilating the
constricted airway. Respiratory function is normal-
ized as much as possible to improve the patients’
quality of life (QOL) and enable them to lead a nor-
mal and healthy life.
1.3. Diagnosis of Adult Asthma
Diagnosing mild asthma without either wheezing or
dyspnea is sometimes difficult. Generally, clinical di-
agnosis of asthma is based on the following factors:
(i) repetitive symptoms such as paroxysmal dyspnea,
Adult Asthma
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wheezing, chest tightness, and cough; (ii) reversible
airflow limitation; and (iii) exclusion of other cardio-
pulmonary diseases (Table 2). The diagnostic criteria
for asthma have not been established. Instead, the
signs suggestive of asthma are presented in Table 3.
1.3.1. Recurrence of paroxysmal dyspnea,
wheezing, chest tightness, and cough
Asthma is characterized by repeated exacerbations
that occur amid symptom-free intervals and develop
even at rest. Patients with asthma may experience
dyspnea (choking) during exercise and laborious
work. Asthma with such symptoms, occurring over
the past 12 months, is called current asthma. The di-
agnosis of asthma is supported by a history of (i) the
development and persistence of dyspnea; (ii) emer-
gency room visits and hospitalization owing to parox-
ysmal dyspnea, (iii) improvement of symptoms when
using an antiasthmatic drug, and (iv) dyspnea caused
by exposure to certain triggering factors.
1.3.2. Reversible airflow limitation4
Wheezing and dyspnea during attacks are caused by
reversible airway narrowing, which develops in the
airways diffusely and ranges from mild to severe. In
its mild form, it can be detected only by respiratory
function tests, while its severe form could even in-
duce near-fatal exacerbations. The peak expiratory
flow (PEF) and forced expiratory volume in one sec-
ond (FEV1) differ markedly between exacerbations
and controlled periods. Asthma-specific alterations in
PEF and FEV1 have not been established, but a diur-
nal variation in PEF of 20% and higher suggests
asthma. Reversible airflow limitation is regarded as
significant when FEV1 is increased by 12% or more
and 200 mL or more of the absolute volume after β2-
agonist inhalation. If the increase is below that level
after β2-agonist inhalation, reversibility may be de-
tected after oral corticosteroid administration for 2 to
3 weeks. In addition, even if no significant difference
is noted in respiratory function tests before and after
β2-agonist inhalation, asthma is still suspected when
there is a significant difference (20%) between the
PEF rates before using a bronchodilator in the early
morning and those after inhaling a β2-agonist be-
tween 12:00 pm and 14:00 pm.
1.3.3. Airway hyperresponsiveness5,6
The airway is contracted by stimuli to which healthy
individuals show no response. A standard quantita-
tion method of the Japanese Society of Allergology to
monitor the changes in FEV1 or a method with an As-
tograph, which measures respiratory system imped-
ance, can be used. In the former method, a patient in-
hales a bronchoconstrictor (e.g., acetylcholine, meth-
acholine, or histamine) for 2 min each before the as-
sessment of FEV1. PC20 (i.e., a concentration to re-
duce FEV1 by 20%) and PD20 (i.e., a cumulative dose
during that time) represent airway responsiveness. In
the latter method, a patient automatically inhales seri-
ally diluted methacholine. Airway hyperresponsive-
ness is assessed as Dmin, the concentration of meth-
acholine at which airway resistance starts to increase.
Both methods are load tests that induce airway nar-
rowing; thus, patients with decreased respiratory
function should be treated with caution. A desirable
baseline percentage of FEV1 against a predicted value
(%FEV1) is 70% or higher.
1.3.4. Atopic state
Specific IgE antibodies against various environmental
allergens indicate an atopic state.
1.3.5. Airway inflammation
Increased percentages of eosinophils, high eosinophil
cationic protein values, and creola bodies consisting
of exfoliated airway epithelial cells, detected by spu-
tum examination, indicate allergic airway inflamma-
tion.7 An increased fraction of exhaled nitric oxide
(FeNO) also suggests eosinophilic airway inflamma-
tion, and is often observed in untreated asthma.8,9 An
increased eosinophil count in the peripheral blood
and elevated serum levels of eosinophil cationic pro-
tein also suggest airway inflammation.
Of the above signs, respiratory symptoms (1.3.1.)
and reversible airflow limitation (1.3.2.), as well as
asthma symptoms not caused by other cardiopulmon-
ary diseases (1.3.6.) are diagnostically important. If
the respiratory function is normal, the presence of
airway hyperresponsiveness (1.3.3.) and allergic air-
way inflammation (1.3.5.) support the diagnosis of
asthma.
1.3.6. Differential diagnosis
A comprehensive diagnosis should be made if bound-
ary regions of asthma-like symptoms, caused by
other cardiopulmonary diseases, or a state coexisting
with asthma are considered (Table 2).
1.4. Classification of the Severity of Asthma and
Asthma Exacerbation
Assessment of the severity of asthma and its exacer-
bation is important for the management of asthma
and a stepwise approach to pharmacotherapy (Table
4). The severity of untreated asthma is classified as
mild intermittent, mild persistent, moderate persis-
tent, or severe persistent (Table 4). These categories
correspond to the recommendation of treatment
steps from 1 to 4, respectively (Table 5). In patients
receiving treatment, the symptoms and the present
treatment step determine the actual severity (Table
6). The classification of exacerbations according to
severity is presented in Table 7.
1.5. Intractable Asthma
Intractable asthma is one of the most severe and per-
Ohta K et al.
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Table　4　Classi cation of asthma severity based on clinical ndings before treatment (adults)
Severity† Mild intermittent Mild persistent Moderate persis-tent Severe persistent
Features of 
asthma 
symptoms
Frequency Less than once a week
Once or more a 
week, not every 
day
Every day Every day
Intensity
Mild and brief
 
 
Short-acting 
inhaled β2 agonist 
is needed almost 
every day
Symptoms at 
night
Less than twice a 
month
Twice or more a 
month
Once or more a 
week Frequently
PEF
FEV1‡
%FEV1, %PEF ≥80% ≥80% ≥60%, <80% <60%
<20% 20-30% >30% >30%
†Determine the severity based on the presence of any one of the 
‡In patients with severe or long-standing symptoms, severity may be underestimated when determined based on symptoms. Respiratory
function indicates the objective severity of airway obstruction. Its variation is associated with airway hyperresponsiveness. %FEV1, (FEV1 
measured value/FEV1 predicted value) × 100; %PEF, (PEF measured value/PEF predicted value or the best value) × 100.
Disturbs daily
life or sleep
once or more a
month
Disturbs daily
life or sleep
once or more a
week
Restricts daily
life
features.
Frequently exacer-
bated even under 
treatment
Diurnal variation
of PEF
sistent types of asthma, with daily presence of symp-
toms, even if step 4 treatment is administered, involv-
ing inhaled corticosteroids (ICSs), long-acting β2-
agonists (LABAs), leukotriene receptor antagonists
(LTRAs), and theophylline (Table 5, 6). Additional po-
tential underlying diseases such as aspirin-
exacerbated respiratory disease (AERD; also known
as aspirin-intolerant asthma and aspirin-induced
asthma, AIA), eosinophilic granulomatosis with poly-
angiitis (EGPA; also known as Churg-Strauss syn-
drome, CSS) and other systemic vasculitis syn-
dromes, and allergic bronchopulmonary mycosis
(ABPM), represented by allergic bronchopulmonary
aspergillosis (ABPA), should be considered in pa-
tients requiring continuous oral corticosteroid ad-
ministration.
2. Epidemiology of Asthma
2.1. Changes in Asthma Prevalence over Time
Asthma prevalence has been rapidly increasing in re-
cent years. An International Study of Asthma and Al-
lergies in Childhood (ISAAC) survey was conducted
across Japan to examine the prevalence of asthma at
specific time points. The mean prevalence in Japan
was estimated to have increased from about 1% to 10%
or higher in children and to about 6% to 10% in adults
since the 1960s. In addition, according to a survey
conducted over several years, in which the same phy-
sicians used the same protocol in subjects with the
same background (Table 8),10,11 a 1.5- to 2-fold in-
crease in the prevalence of asthma was reported
every 10 years. In a survey of adult asthma among the
citizens of Fujieda City in Shizuoka Prefecture con-
ducted in 1985, 1999, and 2006, the prevalence of
adult asthma has been increasing, while the latest
studies of children in Western Japan have shown the
decrease in the prevalence of asthma (Table 8).
2.2. Regional Differences in Asthma Prevalence
The ISAAC Steering Committee reported notable re-
gional differences in the prevalence of asthma: 3.5% in
Indonesia, 34.8% in Costa Rica in 6- to 7-year-old sub-
jects, 3.0% in Albania, and 32.3% in the Isle of Man in
13- to 14-year-old subjects. The prevalence in Japan
was slightly lower than that in Europe and the USA
(e.g., Fukuoka City, 13%). A comparison of the Euro-
pean Community Respiratory Health Survey and
Japanese studies showed that the prevalence of
asthma in Japan was lower (8.1%), although the sur-
veys were conducted in different years (Table 9).12
2.3. Male-to-Female Ratio
The prevalence of asthma is more common in men at
an early age worldwide; however, after puberty, the
prevalence is more common in women (Fig. 1). At
the onset of asthma, the male-to-female ratios in Ja-
pan were 1.4 during infancy (0-5 years of age), 1.0
during childhood (6-17 years of age), and 0.8 in adult-
hood (18 years of age and older).
2.4. Number of Patients
According to the 2011 Statistical Information of the
Japanese Ministry of Health, Labour, and Welfare,
the number of patients with asthma, who had contin-
Adult Asthma
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Table　5　Treatment steps for asthma
Treatment step 1 Treatment step 2 Treatment step 3 Treatment step 4
Long-term 
management 
agents
Basic 
treatment
Inhaled corticoste-
roid (low dose)
Inhaled corticoste-
roid (low to medium 
doses)
Inhaled corticoste-
roid (medium to 
high doses)
Inhaled corticosteroid
(high dose)
If the above agent 
cannot be used, 
use one of the fol-
lowing agents.
・LTRA
・Theophylline sus-
tained-release 
preparation
(unnecessary for 
rare symptoms) 
If the above agent 
is ineffective, con-
comitantly use one 
of the following 
agents.
・LABA
(a compounding 
agent can be 
used)
・LTRA
・Theophylline sus-
tained-release 
preparation
Concomitantly use 
one or more of the 
agents below.
・LABA
(a compounding 
agent can be 
used)
・LTRA
・Theophylline sus-
tained-release 
preparation
Concomitantly use 
multiple agents of  
those below.
・LABA
(a compounding 
agent can be used)
・LTRA
・Theophylline sus-
tained-release prep-
aration
If poorly controlled 
with all of the above 
agents, add either 
or both of the agents 
below.
・Anti-IgE antibody‡
・Oral corticosteroid§
Additional 
treatment
Antiallergics other 
than LTRA†
Antiallergics other 
than LTRA†
Antiallergics other 
than LTRA†
Antiallergics other 
than LTRA†
Exacerbation treatment¶ Inhaled SABA Inhaled SABA Inhaled SABA Inhaled SABA
LTRA, leukotriene receptor antagonists; LABA, long-acting β2 agonist; SABA, short-acting β2 agonist.
†Antiallergics refer to mediator antireleasers, histamine H1 antagonists, thromboxane A2 inhibitors, and Th2 cytokine inhibitors.
‡Anti-IgE antibody is indicated for patients who are positive for perennial inhaled allergen with serum total IgE value of 30-700 IU/mL.
§Oral corticosteroids are intermittent administration for a short period. Keep the minimum maintenance dose if a patient cannot be con-
trolled by enhanced treatment with other agents and short intermittent administration.
¶Management against mild 
In steps 2 and 3 of the treatment, in patients treated with a combination of budesonide/formoterol as a controller, if used as a rescue, the 
agent  should be used within the maximum number of uses for each time and day. The maximum number of uses is generally up to 8 inhala-
tions/day; however, temporarily, it can be used up to 12 inhalations/day (for 3 days: budesonide, 1920 μg/day; formoterol 54 μg/day). When 
more than 8 inhalations/day of budesonide/formoterol are needed, a physician should be consulted.
exacerbations is shown. For other exacerbations, refer to Table 22, 23.
ued to visit the hospital until the survey in October
2011, was 1,045,000 (521,000 men and 523,000
women). The number was calculated as the number
of hospitalized patients + new outpatients + second
visit outpatients × average visit interval × survey coef-
ficient. Medical treatment rates in the hospital and
outpatient settings are in Table 10. In a large-scale
telephone survey, conducted in 2011 (Asthma Insight
and Reality in Japan, AIRJ2011), the percentage of pa-
tients who experienced symptoms within a month
was 62% (adults) and 60% (children). The percentage
of patients who were using ICSs was 34% (adults) and
20% (children).11
2.5. Deaths from Asthma13
According to the Vital Statistics of the Japanese Min-
istry of Health, Labour and Welfare, the number of
patients (of all ages) who died from asthma has
largely decreased in recent years. The number
stopped decreasing at a rate of 4.5 to 5.0 per 100,000
population around 1975, then transiently increased in
1995, and decreased again after 1997, reaching its
lowest point of 1.5 per 100,000 population (1,874
deaths) in 2012 (Fig. 2, 3). In particular, the number
of patients who died from asthma at an early age has
markedly decreased, and, on the other hand, about
90% of asthma deaths have occurred among elderly
subjects aged 65 years or older (Fig. 4).
3. Patient Education and Physician-Patient
Relationship
3.1. Educational Needs
It is required for patients to have a certain amount of
knowledge in order to create a good relationship with
medical professionals and to become capable of self-
management. Sufficient patient education regarding
asthma reduces the prevalence and mortality of
asthma, improves the patients’ QOL, and reduces
medical expenses.14 Effective education of patients in-
cludes the provision of a written self-management
plan (action plan) that outlines the issues related to
severity, self-management, and self-assessment of
Ohta K et al.
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Table 6 Classi cation of asthma severity based on the present treatment (adults)
Present treatment step
Patient’s symptoms in the present
treatment Treatment step 1 Treatment step 2 Treatment step 3 Treatment step 4
Controlled†
Mild intermittent Mild persistent Severe persistent・No symptoms
・No symptoms at night
Mild intermittent‡
Mild intermittent Mild persistent Severe persistent
・Less than once a week
・Mild and brief
・Less than twice a month at night
Mild persistent§
Mild persistent Severe persistent Severe persistent
・Once or more a week, not every
day
・Once or more a month, disturbs
everyday life and sleep
・Twice or more a month at night
Moderate persistent§
Severe persistent Severe persistent
・Every day
・Requires short-acting inhaled β2
agonist almost every day
・Once or more a week, disturbs
everyday life and sleep
・Once or more a week at night
Severe persistent§
Severe persistent Severe persistent Severe persistent
・Frequently exacerbated even un-
der treatment
・Every day
・Restrict everyday life
・Frequently at night
†Consider step-down after continued treatment for 3-6 months.
‡Enhance treatment at each step.
§Check compliance with treatment, and consider step-up as needed.
Moderate
persistent
Moderate
persistent
Moderate
persistent
Moderate
persistent
Most severe
persistent
Most severe
persistent
asthma, instructions on the use of medications, and
timing of drug administration.14
3.2. Subjects
Education should be provided to patients, their fami-
lies, neighbors, and caretakers for the elderly. It is
also important for general physicians and medical
staff to update their knowledge of asthma.
3.3. Contents
Since asthma is a chronic disease, the need for long-
term management must be explained to patients. Pa-
tients, physicians, and medical staff should exchange
information and discuss expected outcomes and any
concerns regarding treatment. In addition, the as-
pects of asthma management listed in Table 11
should be discussed with patients. PEF monitoring is
important to avoid and manage exacerbations. Pa-
tients should receive instructions on the measure-
ment of PEF and the importance of PEF measure-
ment (Table 12). Physicians should acquaint patients
with the concept of prophylactic treatment and review
the self-management plan with them if asthma gets
worse.
3.4. Educators
Specialists in asthma cannot devote their whole time
on patient education. Therefore, nonspecialists (gen-
eral physicians) together with nurses, public health
nurses, and pharmacists should also participate in
education, and community-driven education is de-
sired.
3.5. Places for Education
Education is a continuous task and is provided
through events held by specialized institutions,
health centers, patient support groups, and through
distribution of various teaching materials. Ideally,
medical personnel training on patient education
should continue at health centers, school, and other
Adult Asthma
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Table　7　Classi cation of asthma symptoms and exacerbation severity (adults)
Exacerbation 
severity† Dyspnea Exertion
Laboratory data§
%PEF SpO2 PaO2 PaCO2
Dyspnea but no 
trouble with lying 
down
Slight dyspnea
Dyspnea with 
trouble with lying 
down
Difficulty in 
moving
Difficulty in 
walking
60-80% 91-95% >60 mmHg <45 mmHg
Dyspnea, cannot 
move
Abasia
Difficulty in speak-
ing
<60% ≤90% ≤60 mmHg ≥45 mmHg
Serious‡
Respiratory insuf-
ciency
Cyanosis
Respiratory arrest
Anepia
Akinesia
Confusion, impaired 
consciousness, 
incontinence
Immeasurable ≤90% ≤60 mmHg ≥45 mmHg
†Determine exacerbation severity based on the extent of dyspnea, referring to other items. If symptoms of different exacerbation intensi-
ties coexist, use more severe one.
§Refer to measured values after bronchodilator administration.
≥80% ≥96% Normal <45 mmHg
Dyspnea on
exertion Almost normal
Wheezing/chest
tightness
Mild (mild attack)
Moderate (moder-
ate attack)
Severe (severe 
attack) 
‡Serious conditions, such as respiratory attenuation or arrest, anepia, impaired consciousness, and incontinence are regarded as 
emergency.
Table　8　Prevalence of bronchial asthma
Age (yr) Region Year analyzed Methods n Prevalence (%)
Children  6-12
11 Prefectures 
in Western 
Japan
1982
ATS-DLD
55,388 3.2
1992 45,674 4.6
2002 35,582 6.5
2012 33,902 4.7
Adults
≥15
Fujieda, 
Shizuoka
1985 Original questionnaire 12,152 3.14
≥15 1999 Original questionnaire + ATS-DLD  3,829 4.15
20-79 2006 ECRHS  2,710 7.2
ATS-DLD, American Thoracic Society-Division of Lung Diseases; ECRHS, European Community Respiratory Health Survey.
facilities.
In Japan, information on asthma and educational
activities are provided by various groups and associa-
tions such as the Japanese Society of Allergology (htt
p:www.jsaweb.jp), Japanese Society of Pediatric Al-
lergy and Clinical Immunology (http:www.jspaci.j
p), Japan Allergy Foundation (http:www.jaanet.or
g), Independent Administrative Institution, Environ-
mental Restoration and Conservation Agency of Ja-
pan (http:www.erca.go.jp), and the Japanese Coun-
cil for Quality Health Care (http:minds.jcqhc.or.jpi
ndex.aspx).
3.6. Quality of Life
The assessment of QOL is important in asthma man-
agement, as in other chronic diseases. QOL means
general well-being, according to the Global Initiative
for Asthma, and is useful for the analysis of morbid-
ity. In addition to the Nottingham Health Profile and
SF-36 Health Status Questionnaire, the Asthma Qual-
ity of Life Questionnaire and Asthma Health
Questionnaire-33-Japan (AHQ-33J), prepared by the
Japanese Society of Allergology, are often used. The
AHQ-33J is reproducible, reliable, and useful for the
assessment of social, familiar, and emotional factors.
Ohta K et al.
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Fig.　1　Number of patients with asthma in Japan, by age and sex.
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Fig.　2　Asthma mortality rates in Japan (1950-2012).
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Table　10　Medical treatment rates for bronchial asthma in
Japan
Total In-hospital Outpatient
1999 132 12 120
2002 120  9 111
2005 122  7 115
2008  93  4  88
2011 107  3 103
per 100,000 population
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Fig.　3　Number of deaths from asthma in Japan (1950-
2012).
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Table　11　
- Diagnosis
- Differences between reliever agents and controller agents
- How to use an inhaler
- Instructions for prophylaxis
- Signs of asthma exacerbation
- PEF monitoring
- Self-management plan based on instructions
- How and when to visit clinics
Physician’s instructions for  patients with asthma
4. Asthma Medications
4.1. Asthma Medication Plan for the Long-Term
Management of Adult Asthma
4.1.1. Agents
Asthma medications are divided into 2 types: control-
ler agents used continuously for long-term manage-
ment (controllers) and reliever agents used for a
short period to treat asthma symptoms (relievers).
They are administered via inhalation, oral route, in-
jection (drip infusion, subcutaneous, or intramuscu-
lar), or skin patch. Inhalation using a pressurized
metered-dose inhaler (pMDI) requires synchronized
inhalation of a drug with its release and breath hold-
ing for drug deposition to the airways. A dry powder
inhaler (DPI) requires enough inspiratory flow.
Nebulizer inhalation is often used in patients with
asthma attacks, children, or aged patients who cannot
properly use a pMDI or DPI.
(1) Agents for long-term management (Control-
lers)
Agents to alleviate and eliminate asthma symptoms,
and to normalize and maintain respiratory functions
are called controllers. They are classified based on
their mechanisms of action (Table 13).
a) Corticosteroids (steroids): corticosteroids are
currently the most effective anti-inflammatory agents
for asthma treatment.15 The important mechanisms
of action include (i) inhibiting infiltration of inflamma-
tory cells into the lungs and airway,16 and inhibiting
the migration and activation of inflammatory cells; (ii)
reducing vascular permeability; (iii) suppressing air-
way secretion; (iv) inhibiting airway hyperresponsive-
ness; (v) inhibiting cytokine production; (vi) promot-
ing the effects of β2-agonists17; and (vii) inhibiting
arachidonic acid metabolism in cells other than hu-
man mast cells and the production of leukotrienes
and prostaglandins. Four forms of steroids are avail-
able: for intravenous, intramuscular, oral, and inhaled
use. Steroids used for long-term management of
asthma are usually ICSs. An oral corticosteroid
should only be used when control of asthma cannot
be achieved with ICSs. An aqueous suspension of
triamcinolone acetonide for an intramuscular injec-
tion should not be used because of its adverse effects.
ICSs have been shown to (i) reduce asthma symp-
toms; (ii) improve QOL and respiratory function; (iii)
alleviate airway hyperresponsiveness18; (iv) inhibit
airway inflammation; (v) reduce the frequency and
severity of acute exacerbations19; (vi) reduce the
maintenance dose of ICSs for a long period of time;
(vii) reduce the medical expenses associated with
asthma; (viii) inhibit airway remodeling; and (ix) re-
duce the rate of deaths from asthma. Furthermore,
once asthma symptoms have developed, an early ad-
ministration of an ICS (early intervention) will de-
crease the frequency of acute exacerbations.20 How-
ever, asthma cannot be cured by the treatment and
cannot be controlled if the treatment is discontin-
ued.18 In addition, poor compliance with ICS admini-
stration increases the number of emergency room
visits and hospitalizations due to asthma exacerba-
tions.
In step 4 of treatment (severe asthma), oral corti-
costeroids are used as long-term management agents
Ohta K et al.
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Table　12　Signifi cance of peak expiratory fl ow monitoring
1. Diagnosis of asthma
Diurnal variation in peak expiratory fl ow is useful for elucidation of reversible airfl ow limitation
2. Accurate evaluation of airway obstruction and asthma severity
Patients with asthma often demonstrate discrepancy between symptoms and actual  airway obstruction
3. Objective evaluation of the efficacy of asthma medications
4. Self-evaluation and management
Adequately educated patients can assess their own condition and the efficacy of drugs
Table　13　Controllers (agents for long-term management)
stsinogatna rotpecer eneirtokueL .4sdioretsocitroC .1
1) I etardyh tsakulnarP )isdioretsocitroc delahn
 rlukast
muidos tsakuletnoM )iiietanoiporp enosacitulF )ii
noitaraperp esaeler-deniatsus enillyhpoehT .5edinoseduB )iii
-itnA .6edinoselciC )vi IgE antibody
v) Mometasone furoate Omalizumab
2) Oral corticosteroids
2. Long-acting β2 agonists
1) Inhalants
Salmeterol xinafoate
2) Patch
Tulobuterol
3) Oral medicines
Procaterol hydrochloride
Clenbuterol hydrochloride
Formoterol fumarate
Tulobuterol hydrochloride
Mabuterol hydrochloride
3. Combination inhaler of corticosteroid/long-acting β2 agonist
xinafoate
2) Combination inhaler of budesonide/formoterol fumarate
7. Antiallergics other than leukotriene receptor antagonists
1) Mediator antireleasers
Sodium cromoglicate, tranilast, amlexanox, repirinast, 
ibudilast, tazanolast, and pemirolast potassium
2) Histamine H1 receptor antagonists
Ketotifen fumarate, azelastine hydrochloride, oxatomide, 
mequitazine, and epinastine hydrochloride
3) Thromboxane inhibitors
Ozagrel hydrochloride
Seratrodast
4) Th2 cytokine inhibitor
Suplatast tosilate
8. O
3) Combination inhaler of fluticasone propionate/formoterol 
fumarate
4) Combination inhaler of fluticazone furate/vilanterol trife-
natate
i) Thromboxane-A2 synthesis inhibitor
ii) Thromboxane-A2 receptor antagonist
to complement ICSs, supplement adrenocortical func-
tions, and reduce the levels of systemic inflammatory
cells and inflammatory substances. However, oral
corticosteroids are used for short-term intermittent
administration, or are used at a minimum mainte-
nance dose when continuous administration is re-
quired.
As shown in Table 14, ICSs commercially available
in Japan in 2014 include fluticasone propionate (FP),
budesonide (BUD), beclomethasone dipropionate
(BDP), ciclesonide (CIC), mometasone furoate (MF)
and fluticasone furoate. FP, BUD, and MF are also
available as a DPI. On the other hand, pMDIs using
hydrofluoroalkane (HFA) as a base are used for FP,
BDP, and CIC administration. The mean particle
sizes of these agents are 6 μm > FP-DPI > FP-HFA >
BUD-DPI > MF-DPI > CIC-HFA = BDP-HFA > 1 μm.
These agents are extensively dispersed in the airway,
with smaller particles reaching further into the pe-
ripheral airway.21 In addition, BUD inhalation suspen-
sion, inhaled using a nebulizer, has been recently in-
troduced as a new formulation. A jet nebulizer is rec-
ommended for BUD inhalation suspension, but an ul-
trasonic nebulizer is unsuitable. To prevent adverse
effects caused by BUD inhalation suspension, agents
that come in contact with the face should be wiped
off, and gargling and water intake are important. FF
is available only as a combination with a LABA, vilan-
terol triphenylacetate, and is used once daily.
The dosage of ICSs is classified into a high dose
Adult Asthma
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Table　14　Device for inhaled corticosteroids
pMDI
 (Pressurized metered dose inhaler)
DPI
 (Dry powder inhaler)
BDP (beclomethasone dipropionate) BDP-HFA (Qvar®) None
® Air) FP-DPI (Flutide
® Diskus, Flutide® 
Diskhaler)
Combination inhaler with SM (sal-
meterol xinafoate) FP/SM HFA (Adoair
® aerosol) FP/SM DPI (Adoair® Diskus)
BUD (budesonide) N PD-DUBeno I (Pulmicort® Turbuhaler)
Combination inhaler with FM (for-
moterol fumarate hydrate) N trocibmyS( MF/DUBeno
® Turbuhaler)
CI C )edinoselcic( C IC-HFA (Alvesco®) None
MF (mometasone furoate) N PD-FMeno I (Asmanex® Twisthaler)
Combination inhaler with FM (for-
moterol fumarate hydrate) FP/FM (Flutiform
®) None
FF (fluticazone furate)
Combination inhaler with VI (vilanterol 
trifenatate)
None FF/VI-DPI (Relvar®Ellipta)
Table　 　Recommended doses of inhaled corticosteroids by treatment steps
BDP-HFA 100-200 μg/day
FP-HFA 100-200 μg/day
CIC-HFA 100-200 μg/day
FP-DPI 100-200 μg/day
BUD-DPI 200-400 μg/day
BIS 0 yad/gm 5.
MF-DPI 100-200 μg/day
Treatment steps 1-2 / Low doseAgent Treatment step 4 / High doseTreatment steps 2-3 / Medium dose
400 μg/day
400 μg/day
400 μg/day
400 μg/day
800 μg/day
1.0 mg/day
400 μg/day
800 μg/day
800 μg/day
800 μg/day
800 μg/day
1600 μg/day
2.0 mg/day
800 μg/day
15
(the highest dose covered by health insurance), me-
dium dose (half of the high dose), and low dose (half
of the medium dose) (Table 15). ICSs are effective
even at relatively low doses (e.g., 200 μg FP) in
adults. However, if the dosage exceeds the high
dose, further effects proportional to the dose cannot
be achieved, and the risk of adverse effects is
higher.22 Thus, in controlling asthma, a more favor-
able outcome can be achieved by adding one or more
controller other than ICSs rather than by simply in-
creasing the dose of an ICS.19 However, severe acute
exacerbations can be alleviated by increasing an ICS
dose.19 Smoking reduces the effects of ICSs and im-
pairs the respiratory function in patients with
asthma.23
Apart from localized adverse effects, such as oro-
pharyngeal candidiasis and hoarseness, ICSs have a
few systemic adverse effects, including the effects on
the eyes (cataract and glaucoma), skin (skin thinning
and hemorrhage), bones (osteoporosis), and inhibi-
tory effects on the hypothalamic-pituitary-adrenal
function.24 After inhalation, gargling is essential to al-
leviate oropharyngeal symptoms and reduce systemic
absorption.
While conventional doses are generally acceptable,
a careful follow-up is necessary when high doses are
used. BUD-DPI, administered during early preg-
nancy, has not been reported to cause congenital mal-
formation or to have any effects on the course of
pregnancy.25 The US Food and Drug Administration
(FDA) has classified the safety of BUD-DPI in preg-
nant women as Category B. There is no evidence of
an increased risk of respiratory tract infection, includ-
ing tuberculosis, caused by ICSs in patients with
asthma, and ICSs are not contraindicated in patients
with active tuberculosis.
b) LABAs: β2-agonists are potent bronchodilators
that enhance airway mucus removal via epithelial cilia
activation, and are administered via inhalation, patch,
or oral route. As controllers, β2-agonists should be
Ohta K et al.
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Table　1 　Daily doses of combination inhaler of corticosteroids and long-acting β2 agonists
esod hgiHesod muideMesod woL
FP/SM (DPI)
100 μg/dose, 1 dose b.i.d. 250 μg/dose, 1 dose b.i.d. 500 μg/dose, 1 dose b.i.d.
200 μg/100 μg 500 μg/100 μg 1000 μg/100 μg
BUD/FM† (DPI)
One dose b.i.d. Two doses b.i.d. Four doses b.i.d.
320 μg/9 μg 640 μg/18 μg 1280 μg/36 μg
FP/SM (pMDI)
50 μg/dose, 2 doses b.i.d. 125 μg/dose, 2 doses b.i.d. 250 μg/dose, 2 doses b.i.d.
200 μg/100 μg 500 μg/100 μg 1000 μg/100 μg
FP/FM (pMDI)
FF/VI (DPI)
50 μg/dose, 2 doses b.i.d.
200 μg/20 μg
125 μg/dose, 2 doses b.i.d.
500 μg/20 μg
125 μg/dose, 4 doses b.i.d.
1000 μg/40 μg
100 μg/dose, 1 dose s.i.d.
100 μg/25 μg
100 μg/dose, 1 dose s.i.d.
100 μg/25 μg 
or
200 μg/dose, 1 dose s.i.d.
200 μg/25 μg
200 μg/dose, 1 dose s.i.d.
200 μg/25 μg
6
FP, fluticasone propionate; SM, salmeterol xinafoate; BUD, budesonide; FM, formoterol fumarate; FF, fluticazone furate; VI, vilanterol 
trifenatate.
†Indication in a delivered dose.
used concomitantly with ICSs. When a LABA is com-
bined with an ICS, the steroid increases the number
of β2-receptors, and the β2-agonist promotes the nu-
clear translocation of steroid receptors, thereby en-
hancing the steroid action. Furthermore, the com-
bined therapy of an ICS and LABA can allow clini-
cians to reduce the dose of an ICS26 and increase the
number of patients with well-controlled asthma. The
combination of an ICS and LABA is more effective
than an ICS with sustained-release theophylline.27
Salmeterol xinafoate is an inhaled LABA that can-
not be used alone for the treatment of asthma28; how-
ever, it has high synergistic effects when combined
with an ICS.29 Conventional oral LABAs include pro-
caterol hydrochloride, clenbuterol hydrochloride,
and mabuterol hydrochloride. A tulobuterol patch,
which was developed in Japan, is a long-acting agent
with a bronchodilator action that continues for 24 h. It
is useful in patients for whom inhalation and oral ad-
ministration are difficult. Its clinical usefulness when
used concomitantly with an ICS has been reported.30
LABAs have a high safety profile in any formulation.
However, adverse effects include tremor, palpitation,
and tachycardia, and occur most frequently for oral
agents, followed by patches, and inhaled agents.
When adverse effects are observed, the dose should
be reduced or administration should be discontinued
according to the complaint. Serious adverse effects
include a decreased serum potassium level. LABAs
should be used more carefully in patients with
ischemic heart disease, hyperthyroidism, and diabe-
tes mellitus. In addition, the adverse effects of the tu-
lobuterol patch include skin itching or rash (or both)
around the patch area.
c) Combination agents of ICS and inhaled LABA
(ICSLABA) (Table 16): In Japan, fluticasonesal-
meterol, BUDformoterol, and new drugs such as flu-
ticasoneformoterol and fluticasone furoatevilan-
terol are currently available as combination agents of
ICSLABA, which are more effective than when in-
haled separately.31 They have the following advan-
tages: (i) the number of inhalations can be reduced;
(ii) excellent compliance can be achieved; and (iii)
the use of LABAs alone can be avoided. Recently, it
has been reported that mild asthmatic patients can be
controlled by combination agents used once daily.32
Furthermore, the rescue use of BUDformoterol in-
stead of a short-acting β2-agonist (SABA) can improve
asthma symptoms and reduce the rate of asthma ex-
acerbations.33 However, it is important to alleviate
asthma symptoms and normalize and maintain respi-
ratory functions for long-term management by the
regular use of ICSs and combination agents. Accord-
ing to the 2010 FDA recommendations, asthma treat-
ment should be based on the assessment of the con-
trol level when using these combination agents.34 If
the simultaneous use of a LABA can be discontinued
when asthma is well controlled, a switch to an ICS
alone can be made. However, it remains controversial
whether a continuing use of combination agents can
reduce the rate of severe exacerbations compared to
ICSs alone after a good control of asthma is
achieved.35,36
d) LTRAs: leukotrienes (LT) C4, D4, and E4 are
called cysteinyl LTs (CysLTs), and their respective
receptors are CysLT1, CysLT2, and CysLT3. A cur-
rently available LTRA is a CysLT1 receptor antago-
nist. Three types of LTRAs are available: pranlukast
hydrate, zafirlukast, and montelukast. LTRAs have a
bronchodilator action and inhibit airway inflamma-
tion, resulting in a significant improvement of asthma
symptoms, respiratory function, inhalation frequency
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of as-needed inhaled β2-agonist, airway inflammation,
airway hyperresponsiveness, dosage of ICSs, asthma
exacerbations, and patients’ QOL.37-39 LTRAs are use-
ful as agents used concomitantly with an ICS in pa-
tients with asthma that cannot be completely con-
trolled even with a medium dose of an ICS, because
the additional administration of LTRAs is as effective
as a double dose of an ICS.40 Compared with LABAs,
LTRAs used in combination with an ICS are less ef-
fective in improving symptoms and respiratory func-
tion and are almost equivalent in preventing exacer-
bations.41 LTRAs are useful for long-term manage-
ment of patients with asthma complicated by allergic
rhinitis, exercise-induced asthma (EIA), and AIA.
Generally, LTRAs alone are less effective compared
with low doses of ICSs, whereas the effects of LTRAs
plus ICSs are reported to be the same as those of LA-
BAs plus ICSs in steroid-naïve asthmatic patients.32,42
In some patients, respiratory function improves
early after the oral administration of an LTRA (at sev-
eral hours at the earliest, on the following day at the
latest); however, anti-inflammatory effects develop
later. Thus, efficacy is generally judged after 2 to 4
weeks after administration. While more reports have
been published on EGPA in patients who have re-
ceived an LTRA than in those who have received
other antiasthmatic drugs, no conclusion has been
reached as to whether an LTRA is directly involved in
the onset of EGPA.43 LTRAs are generally safe drugs,
although zafirlukast should be used with caution be-
cause it may cause severe hepatopathy and interact
with other agents, such as warfarin, since it is me-
tabolized by CYP2C9. LTRAs seem to be relatively
safe for pregnant women.
e) Sustained-release theophylline: sustained-rele-
ase theophylline is a long-acting bronchodilator with
anti-inflammatory effects. It inhibits airway infiltration
of lymphocytes and eosinophils,44 T-cell proliferative
response, cytokine production, apoptosis induction of
eosinophils,45 and recovery of steroid sensitivity
through histone deacetylase reactivation.46 While
sustained-release theophylline is clinically less effec-
tive than ICSs, when used in combination with low-to-
medium doses of an ICS, the same effects as those
obtained with an increased dose of an ICS can be
achieved.47 However, as a concomitant drug with
ICSs, sustained-release theophylline at a dose of 300
to 400 mgday improved airway obstruction to a
lesser extent than LABAs did27 and to a comparable
(the same or slightly lesser) extent than LTRAs did.48
The effective safety range of theophylline is rather
narrow, and the serum theophylline level varies de-
pending on various factors (age, smoking, drug inter-
action, etc.); thus, monitoring of its serum level may
be useful to avoid adverse effects. Anti-inflammatory
effects are obtained at a serum theophylline level of 5
to 10 μgmL, and, importantly, a bronchodilator ac-
tion is achieved in a concentration-dependent man-
ner. No serious adverse effects have been noted at se-
rum theophylline concentrations of up to 20 μgmL.
Monitoring the peak serum theophylline level is diffi-
cult, thus the target level is from 5 to 15 μgmL. The
adverse effects of theophylline include gastrointesti-
nal symptoms such as nausea and vomiting at initial
oral administration. Toxic symptoms caused by in-
creased serum theophylline levels include nausea
and vomiting at first, and may progress to tachycardia
and arrhythmia. In the most severe cases, convul-
sions may occur that can lead to death. In pregnant
women, no effect of theophylline has been noted on
the frequency of fetal disorders as far as appropriate
serum levels are maintained.
f) Anti-IgE antibody: omalizumab is a humanized
antihuman IgE monoclonal antibody that binds to IgE
to inhibit the binding between IgE and the high affin-
ity IgE receptor, thereby decreasing the expression
of the high affinity IgE receptor on tissue mast cells
and circulating blood basophils. Anti-inflammatory ef-
fects have been reported, such as a reduced number
of eosinophils, T cells, B cells, and Th2 cytokine-
positive cells in the sputum and airway tissue and de-
creased serum interleukin (IL)-5 and IL-13 levels.49,50
The dose and frequency of administration are de-
termined based on a dosage conversion table accord-
ing to patient weight and serum IgE level (30-1,500
IUmL) to reduce serum free IgE levels to 10 IUmL
or lower. Omalizumab has the following effects in pa-
tients with a poor control of asthma even despite
treatment with a high dose of ICS: (i) preventing ex-
acerbation; (ii) reducing the freguency of asthmatic
symptoms; (iii) improving QOL; and (iv) reducing a
steroid dose.51 Omalizumab should be used as a
therapeutic agent in step 4 treatment for severe per-
sistent asthma, sensitized to perennial inhalation anti-
gens (mites, animals, fungi, etc.). It is effective in
about 60% of the patients. At 16 weeks after admini-
stration, therapeutic effects are comprehensively
judged based on the frequency of exacerbations,
QOL, respiratory function, and other variables, to de-
termine whether treatment should be continued.52 In
a Japanese clinical study, the PEF rate, FEV1, and the
frequency of exacerbations were significantly im-
proved in poorly controlled patients with the con-
comitant use of a high-dose ICS and one or more con-
troller agents. It is unknown whether treatment can
be discontinued after long-term administration.
The major adverse effects of omalizumab are pain
and swelling at the injection site. An anaphylactic re-
action, reported as a serious adverse effect in 0.1% to
0.2% of the patients overseas, could develop within
2 h after administration (about 70% of the episodes),
but some reactions have been reported to occur after
24 h. Symptoms may develop both in the initial stages
of administration and after longer use. The drug
should be administered with caution because EGPA
may develop due to the reduced amount of systemic
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steroids. No teratogenicity has been reported, and
the antibody is safe for pregnant women, although it
penetrates the placenta.
g) Antiallergic agents other than LTRAs: antialler-
gic agents include either mediator-release suppres-
sants or mediator inhibitors, and are effective in 30%
to 40% of the patients with mild-to-moderate atopic
asthma, although an administration period of 4 to 6
weeks or longer is needed to determine their effi-
cacy. Safety of oral antiallergic agents in fetuses dur-
ing pregnancy has not been demonstrated.
Mediator-release suppressants: the main effect of
mediator-release suppressants is inhibiting the re-
lease of chemical mediators from mast cells. Long-
term use of inhaled disodium cromoglycate (DSCG)
inhibits airway inflammation in patients with atopic
asthma.53
Histamine H1-antagonists: the main effect of these
agents is to antagonize the action of histamine
through H1-receptors. The antagonists are beneficial
for asthma accompanied by allergic rhinitis or atopic
dermatitis. Adverse effects may include sleepiness
and malaise.
Thromboxane-A2 inhibitorsantagonists: throm-
boxane-A2 synthesis inhibitors and thromboxane-A2
receptor antagonists inhibit airway inflammation, im-
prove airway hyperresponsiveness, and improve im-
paired mucociliary transport. Their adverse effects in-
clude a tendency for increased bleeding, thus we
should be cautious about the concomitant use of
other agents with inhibitory effects on platelet aggre-
gation.
Th2 cytokine inhibitor: the major effects of a Th2
cytokine inhibitor, suplatast tosilate, are inhibition of
IL-4 and IL-5 production from Th2 cells, inhibition of
eosinophil infiltration into the airway mucosa, and al-
leviation of airway hyperresponsiveness in patients
with asthma.54 The inhibitors allow to reduce the
dose of an ICS.55
h) New therapeutic agents: a long-acting anti-
cholinergic drug (a long-acting antimuscarinic agent,
LAMA) is the first-line drug in patients with chronic
obstructive pulmonary disease (COPD) and is useful
in asthmatic patients with COPD (asthma-COPD
overlap syndrome). When a LAMA is used in combi-
nation with an ICS in asthmatic patients without
COPD, its effect is comparable to that of a LABA.56
Antibodies against IL-5 and IL-13 are being developed
for patients with severe asthma.57-59
(2) Reliever agents
a) SABAs: SABAs are regarded as reliever agents.
Inhalation therapy using a pMDI, DPI, and nebulizer
shows a comparable or even higher bronchodilator
action compared with oral administration. However,
there are a few adverse effects such as stimulation of
the cardiovascular system, skeletal muscle tremor,
and hypokalemia, which can be reduced using a
spacer. The increasing need for the use of a SABA
may be regarded as an exacerbation, and inhalation
can be repeated as needed. The use of a SABA as a
reliever 5 times or more daily means that controller
agents are necessary. If the effects are not satisfac-
tory after repeated inhalation every 20 min for 1 h,
medical consultation is needed. SABAs are effective
in the prevention of allergen-induced asthma or EIA
and treatment of exacerbations.
b) Oral corticosteroids: for acute asthma attacks
(moderate exacerbations), an oral corticosteroid, to-
gether with a SABA, needs to be administered for a
short period (about 1 week). Prior short-term treat-
ment of asthma symptoms (usually less than 1 week)
with a medium or high dose of an oral corticosteroid
(approximately 0.5 mgkg of prednisolone) prevents
acute exacerbations, decreases emergency visits and
hospital admissions, and reduces the restrictions on
daily life due to asthma attacks. In short-term treat-
ment (less than 2 weeks), a sudden dose reduction or
discontinuation of treatment will not result in adreno-
cortical insufficiency (steroid withdrawal syndrome).
Patient compliance with the treatment regimen
should be reassessed.
c) Theophylline: A single use of oral aminophylline
is used as a reliever agent, and its dose depends on
its serum levels.
d) Inhaled anticholinergics: inhaled anticholiner-
gics have additive effects with β2-agonists on acute
exacerbations. They are especially useful in elderly
patients with asthma -COPD overlap syndrome.
(3) Other agents and therapies
a) Chinese herbal medicines: selection of an agent
is based on the patient’s physical constitution,
strength, and response to disease at the time of ad-
ministration; the empirical process helps distinguish
between responders and nonresponders before ad-
ministration.
b) Other agents: expectorants such as carbociste-
ine and fudosteine may facilitate expectoration, and
macrolides may inhibit neutrophilic inflammation ob-
served in some asthmatic patients. However, accumu-
lated evidence is not sufficient to recommend any of
these agents.
c) Specific immunotherapy: allergen-specific immu-
notherapy is indicated in patients with symptoms
caused by the relevant allergens that cannot be
avoided, patients with allergic rhinitis, and asthmatics
who desire tapering medication or who are intolerant
to some drugs owing to adverse effects. This therapy
induces regulatory T cells, resulting in the inhibition
of cytokine production from Th2 cells and chemical
mediator production from mast cells to improve
eosinophilic airway inflammation and airway hyperre-
sponsiveness.60
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Fig.　5　Effects of individual agents on asthma symptoms in long-term management.
LABA, long-acting β2-agonists; Theophylline, sustained-release theophylline preparation; LTRA, leukotriene 
receptor antagonists. The effect of each drug on asthma symptoms is refl ected by the fi ve shades of gray.
㻌 Bronchodilation Inflammation↓ Remodeling↓ Airway secretion↓
Inhaled corticosteroid 㻌 㻌 㻌 㻌
LABA 㻌 㻌 㻌 㻌
Theophylline 㻌 㻌 㻌 㻌
LTRA 㻌 㻌 㻌 㻌
Anti-IgE antibody 㻌 㻌 㻌 㻌
Table　17　
Well-controlled
 (meet all the criteria)
Insufficiently-controlled
(meet 1 or 2 criteria) Poorly-controlled
Asthma symptoms (in the 
daytime or at night) None Once or more a week
Meet 3 or more criteria of 
insufficient control
Use of reliever None Once or more a week
Limitation of activities, includ-
ing exercise N detcirtseReno
Lung function
(FEV1 and PEF)
Predicted value or <80% of 
the best value
Diurnal (weekly) variation in 
PEF <20 2≥% 0%
Exacerbation None Once or more a year Once or more a month†
†Determine patients with one or more exacerbations a month as being poorly controlled, even if they do not meet the other criteria.
Predicted value or ≥80%
of the best value
Assessment of asthma control
4.1.2. Stepwise treatment plan
(1) Aim of asthma treatment
The aim of asthma treatment is to achieve normal res-
piratory function in the absence of symptoms or ad-
verse effects. In patients with airway remodeling, nor-
mal respiratory function cannot be restored; thus, it
can be assessed based on their best values. The con-
trol status is determined as shown in Table 17, with
the aim to achieve asthma control.
(2) Principles of treatment
A better relationship between patients and physicians
largely depends on the effects of initial treatment,
which focuses on the improvement of asthma symp-
toms. Apart from using therapeutic agents for
asthma, it is important to avoid and eliminate sensitiz-
ing allergens (mites, fungi, cockroaches, animals, pol-
len, and others) and exacerbating factors such as pas-
sive and active smoking and excessive fatigue. Man-
agement of concomitant diseases, such as allergic
rhinitis and COPD, is also important.
Asthma treatment is divided into 4 treatment steps
based on asthma severity. The steps are outlined in
the following section. The aim of drug therapy is to
achieve the maximum effect using the minimum
number of drugs. Symptoms at the initiation of ther-
apy, those at consultation, and therapeutic situation
are comprehensively evaluated to determine the ap-
propriate treatment step. Each controller drug has a
characteristic spectrum of effects based on the evi-
dence of their basic mechanisms of action and clinical
efficacy (Fig. 5). It would be valuable to consider the
features of each drug when multiple drug therapy is
necessary.
(3) Four treatment steps in asthma (Table 5)
Treatment is stepped up when asthma symptoms de-
teriorate or sufficient control cannot be achieved with
current pharmacotherapy. Maintenance therapy is
determined on the basis of asthma symptoms and
PEF. When asthma attack occurs during long-term
management, a SABA should generally be used as a
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reliever. In steps 2 and 3 of asthma treatment, if pa-
tients are treated with a combination of BUD and for-
moterol as a controller, its use as a reliever should
not exceed the maximum number of inhalations for
each use and day as shown in the legend of Table 5.
Caution should be taken when stepping the treatment
down to prevent the aggravation of symptoms, and
the patient should be informed about the treatment
against exacerbations during dose reduction.
a) Step 1 treatment: one (or no) controller agents
plus a reliever agent. A SABA without controllers
may be administered only to patients with rare
asthma symptoms (less than once a month), in whom
no long-term management is needed. It should be
emphasized that many patients with asthma underre-
port their symptoms. For patients who develop symp-
toms once or more a month, a low dose of an ICS is
recommended as a controller agent.20 If ICSs cannot
be used, or adverse effects develop after inhalation,
LTRAs37 or sustained-release theophylline44 can be
used, but their anti-inflammatory activities are infe-
rior to those of ICSs.
b) Step 2 treatment: two controller agents plus a re-
liever agent. In addition to ICSs (low-to-medium
dose), a LABA,28,29 LTRA,41,61 or sustained-release
theophylline47 can be used. A low-to-medium dose of
an ICSLABA can also be used.62 LTRAs should be
considered mainly in patients with coexisting allergic
rhinitis and sympathetic nerve stimulation caused by
a LABA or theophylline. Depending on disease condi-
tions, antiallergic agents other than LTRAs can be si-
multaneously used.
c) Step 3 treatment: Two or more controller agents
plus a reliever agent. In addition to an ongoing treat-
ment with an ICS (medium-to-high dose), a LABA
and LTRA, or a LABA with sustained-release theo-
phylline, or a LABA with both an LTRA and
sustained-release theophylline, are used. A medium-
to-high dose of ICSLABA can also be used.62
d) Step 4 treatment: controller agents plus a re-
liever agent plus additional therapy. In addition to
continuous administration of an ICS (high dose), a
LABA, LTRA, or sustained-release theophylline is
used. A high dose of ICSLABA can also be used.62
When good control of asthma cannot be achieved
even when using a high dose of an ICS in combina-
tion with other drugs, anti-IgE antibody (omalizu-
mab) is effective in poorly controlled patients sensi-
tized to perennial allergens, whose serum total IgE
level is within a therapeutic target range (30-1,500
IUmL).51 The dose of an anti-IgE antibody is deter-
mined based on the total IgE value and body weight,
using a dosage conversion table. Its effects are evalu-
ated 16 weeks after administration, and if effective,
administration is continued. Oral corticosteroids
should be intermittently administered for a short pe-
riod to avoid prolonged administration wherever pos-
sible. Specifically, about 0.5 mgkg or the equivalent
amount of prednisolone is administered for a short
period (usually less than 1 week), and a high-dose
ICS is subsequently used. In patients with insufficient
asthma control, who need prolonged administration
of an oral corticosteroid, a shorter-acting oral corti-
costeroid (prednisolone) can be administered every
day or every other day in the morning to maintain the
minimum dose (5 mg). Caution should be taken
when switching from long-term administration of an
oral corticosteroid to a high-dose ICS because of pos-
sible adrenal insufficiency.
(4) Practical application
a) Selection of treatment steps: in untreated pa-
tients, treatment step is determined on the basis of
asthma symptoms and measurement of pulmonary
function, including such parameters as PEF and
FEV1 (Table 4). Specifically, treatment steps are se-
lected as follows: (i) step 1 treatment for mild inter-
mittent symptoms; (ii) step 2 treatment for mild per-
sistent symptoms; (iii) step 3 treatment for moderate
persistent symptoms; and (iv) step 4 treatment for se-
vere persistent symptoms. In patients who have al-
ready received drug therapy such as controllers,
which is often the case, the treatment step should be
determined according to Table 6. It is important to
maintain good control of asthma throughout treat-
ment (Table 17). If asthma symptoms are not con-
trolled well, intensification of treatment should be
considered. When symptoms occur less than once a
week, intensification of treatment within the same
treatment step should be considered. When asthma
symptoms occur every week or every day, one step-
up or two step-ups are required for good control. In
patients receiving drug therapy, a step-down should
be considered if asthma control continues for 3 to 6
months, based on the assessment of the control
status presented in Table 17.
b) Useful considerations for monitoring asthma
management during follow-up are summarized as fol-
lows.
i) Spirometry: the measurement of pulmonary func-
tion (airflow limitation) is important to determine the
severity of asthma and evaluate effectiveness of treat-
ment.63 The degree of airflow limitation is deter-
mined by reduction in FEV1, %FEV1 (%FEV1 = FEV1
forced vital capacity × 100), and PEF. The decreased
values of V50 and V25 and increased values of the V50-
to-V25 ratio are useful for early diagnosis of peripheral
airway diseases.
ii) PEF: to evaluate the degree of airflow limitation
objectively every day, monitoring of PEF is recom-
mended. It is particularly beneficial in asymptomatic
patients or in those with frequent exacerbations. It
can also be used to determine antigens or exacerba-
tion factors. Diurnal variation of PEF is correlated
with the degree of airway hyperresponsiveness.
Large daily variation of PEF signifies increased air-
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way hyperresponsiveness. Thus, it becomes a good
marker of asthma control.64-66
iii) Asthma diaries and questionnaires: asthma di-
ary, Asthma Control Questionnaire, and Asthma Con-
trol Test are useful for evaluation of asthma cont-
rol.67-69
iv) Percentage of sputum eosinophils: if spontane-
ous sputum is not obtained, sputum can be induced
by inhalation of hypertonic saline. To avoid airway
contraction by hypertonic saline inhalation, the pa-
tient should inhale a SABA prior to hypertonic saline
inhalation. Several reports have demonstrated that
the management of eosinophil-oriented asthma is su-
perior to that of symptom-oriented asthma in reduc-
ing asthma exacerbations.70-72
v) Airway hyperresponsiveness: using the thresh-
old values of airway hyperresponsiveness, better
management can be achieved compared with the
management guided by conventional symptoms and
pulmonary function.73 Because airway hyperrespon-
siveness can be measured only in specialized centers,
the general clinical usefulness of the airway hyperre-
sponsiveness test is limited.
vi) Measurement of FeNO: exhaled NO is released
from inducible NO synthase in airway epithelial cells.
It reflects the degree of airway eosinophilic inflamma-
tion. Because the measurement of FeNO is easy and
noninvasive, it is useful for the diagnosis of asthma
and monitoring of airway inflammation. Moreover,
high levels of FeNO indicate good responsiveness to
steroid treatment.74-79
vii) Other parameters: eosinophil count in the pe-
ripheral blood and specific IgE antibodies are useful
for the diagnosis of asthma. Blood theophylline con-
centration or corticosteroid levels are important to
monitor patients receiving asthma pharmacotherapy.
When asthma is exacerbated, respiratory failure
should be assessed by pulse oximetry and arterial
blood gas analysis. In such cases, blood tests, chest
radiograph, and electrocardiogram should be per-
formed to exclude other diseases.
(5) Management of difficult-to-treat patients
Uncontrolled or partly controlled patients need ade-
quate instruction regarding daily medication, inhala-
tion technique, and management for acute exacerba-
tion and are provided with an asthma diary that re-
cords the doses and timing of asthma medications.
Patients with worsening symptoms are instructed to
follow an emergency manual immediately. In addi-
tion, patients are acquainted with dose reduction
strategies. Furthermore, in case of acute exacerba-
tion, they should have contact information handy,
addresses of emergency hospitals, and an “asthma
notification card,” which enables treating physicians
and other physicians to administer emergency treat-
ment.
Early referral to a specialist is recommended for
patients with underlying diseases such as AIA, EPGA
(CSS), other systemic vasculitis, and allergic bron-
chopulmonary aspergillosis, because, in addition to
the above treatment steps, a continuous administra-
tion of a systemic steroid or immunosuppressant may
be needed.
a) AIA: About 10% of the patients with adult asthma
suffer from an asthma attack immediately or within
1 h after the administration of nonsteroidal anti-
inflammatory drugs (NSAIDs), which have aspirin-
like effects. This type of asthma is called “aspirin-
induced asthma” and about 50% of the cases are re-
fractory asthmatic patients. They often have nasal
polyp and eosinophilic sinusitis. Not only aspirin but
also acidic NSAIDs induce severe asthma attack;
therefore, a physician instructs patients not to use
NSAID-containing oral medicines, suppository, pat-
ches, and ointments for long-term management. A
physician should consider treatment of the complicat-
ing nasal polyp and eosinophilic sinusitis.
In treating acute exacerbations, caution should be
exercised for induction of asthma attack by some
types of steroids. When administration of systemic
steroid is needed in an asthma attack, oral steroids or
intravenous infusion of steroid phosphate esters are
recommended.
b) EPGA (also known as CSS): EPGA is character-
ized by asthma, increase of eosinophil levels in the
blood and tissues, and polyangiitis of many organs.79
The treatment of choice in EPGA is systemic ster-
oids. Poor-prognosis factors (five-factor score) is pro-
posed.80 In patients with severe asthma and cardiac
disease or in steroid-resistant patients, cyclophos-
phamide is used in combination with systemic ster-
oids. Sometimes, an intravenous infusion of immuno-
globulin is administered in treatment-resistant pa-
tients with nerve or cardiac disorder.
c) ABPA: ABPA is a disease characterized by
asthma and lung infiltration induced by abnormal im-
munoreaction against Aspergillus, resulting in irre-
versible destruction of the airway architecture (bron-
chiectasis) and lung fibrosis. In addition to asthma
treatment, systemic steroids are required.81 When
the dose of systemic steroids cannot be reduced, an
administration of antifungal drug, itraconazole,
should be considered.
d) Gastroesophageal reflux disease (GERD):
GERD is a complicating disease in asthmatic patients,
and the symptoms are frequently seen in uncon-
trolled asthmatic patients. Administration of theophyl-
line or oral steroids sometimes exacerbates GERD.
GERD is treated with proton-pump inhibitors. Treat-
ment with proton-pump inhibitors does not necessar-
ily improve asthma control in patients with uncon-
trolled asthma without the symptoms of GERD.
e) Asthma with allergic rhinitis: asthma may be sig-
nificantly complicated by allergic rhinitis. Active com-
plicating allergic rhinitis in asthmatic patient should
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Table　 　
Decreased clearance (increases serum level)
- Aging (50 years or older) and extreme obesity
- Complications, such as hepatopathy, heart failure, virus infection, and fever
- Agents: allopurinol, macrolides (erythromycin, clarithromycin, and roxithromycin), cimetidine, diazepam, new quinolones 
(ENX, CPFX, and TFLX), thiabendazole, propranolol (contraindicated for asthma), etc.
Increased clearance (decreases serum level)
- Smoker (who smoke ≥15 cigarettes/day)
- Agents: barbituric acid, antiepileptics (carbamazepine and phenytoin), rifampicin, isoproterenol, etc.
18
be simultaneously treated.82 Pharmacotherapy for al-
lergic rhinitis may alleviate asthma symptoms and im-
prove airway hyperresponsiveness.83,84 In addition,
an LTRA improves the clinical symptoms in this pa-
tient group. Concomitant use of an LTRA is more ef-
fective in improving airway obstruction due to asthma
than doubling the dose of an ICS.85
f) Asthma with COPD: COPD is an important coex-
isting disease, requiring caution in differential diag-
nosis in elderly patients with asthma. COPD is also
an important disease as comorbidity. Particularly, eld-
erly patients with asthma, who have a smoking his-
tory, should be diagnosed. Since long-acting inhaled
anticholinergics are recommended for COPD, a con-
comitant use of inhaled tiotropium is preferable in
elderly patients with asthma complicated by COPD. A
therapeutic agent should be chosen considering that
a combination inhaler device of a corticosteroid and a
LABA is also effective for COPD.
4.2. Management of Acute Exacerbations in
Adults
4.2.1. Therapeutic agents
(1) Inhaled β2-agonists
Better therapeutic effects can be obtained by re-
peated administration of a small dose (1 to 2 puffs at a
time using a portable pMDI) for a fixed period than
by single administration of a high dose.86 For acute
asthma symptoms, a SABA is inhaled every 20 min
for the first hour and subsequently every hour until
improvement is noted. Inhalation using a spacer is
more effective87 because it causes less adverse ef-
fects. If adverse effects such as marked tremor and
palpitation develop, the inhalation should be discon-
tinued. A nebulizer is effective in allowing continued
inhalation coupled with oxygen. Adding an inhaled
anticholinergic may provide an additive bronchodila-
tor action.88
(2) Subcutaneous injection of adrenaline (0.1%)
Catecholamine formulation (adrenaline, 0.1%) may be
administered when no sufficient effects can be ob-
tained with an inhaled β2-agonist, but caution should
be exercised because arrhythmia, cardiac arrest, and
other adverse effects may develop. Subcutaneous in-
jection of adrenaline (0.1%, 0.1-0.3 mL) provides a
bronchodilator action through the relaxation of the
bronchial smooth muscles (β effect) and the removal
of airway mucosal edema (α effect). Although the ad-
ministration can be repeated every 20 to 30 min,
pulse rate monitoring is desirable and it should be
kept at a rate of 130min and lower. This agent is con-
traindicated in patients with complications such as ar-
teriosclerosis, hyperthyroidism, diabetes mellitus, se-
vere arrhythmia, psychoneurosis, and glaucoma (ex-
cept for open-angle [simple] glaucoma). In addition,
caution should be exercised for the following agents
because of contraindication for concomitant use with
adrenaline: i) inhaled halogen-containing anesthetics
such as halothane (they carry an increased risk of
tachycardia and ventricular fibrillation); ii) antipsy-
chotics (butyrophenones, phenothiazines, iminoben-
zyls, zotepine, and risperidone) and α-blockers (they
may result in hypotension due to epinephrine rever-
sal); iii) catecholamine formulation, such as isoproter-
enol, and adrenergic agents are principally contrain-
dicated unless in emergent cases such as resuscita-
tion (concomitant use may develop arrhythmia, and,
in some cases, cardiac arrest); iv) a tulobuterol patch
may be concomitantly used with caution; however, a
concomitant use with fenoterol is contraindicated.
(3) Theophylline
The effective serum concentration of theophylline is
from 8 to 20 μgmL (<15 μgmL in children), and ad-
verse effects will occur when exceeding this range.
Intravenous infusion of aminophylline (6 mgkg) has
a bronchodilator action and positive effects on the
respiratory drive and respiratory muscles; thus, it is
effective in treating acute asthma attacks.89 Amino-
phylline has additive effects for β2-agonists,89 and its
use decreases hospitalization rates due to asthma at-
tacks. Safer and more sufficient administration can be
achieved by monitoring the level of serum theophyl-
line. For safety reasons, initial administration is con-
ducted with 6 mgkg of aminophylline (250 mgam-
pule) in 200 to 250 mL of isotonic fluid, and the first
half is infused over 15 min and the other half over 45
min when theophylline was insufficiently adminis-
tered before exacerbation and theophylline clearance
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Table　 　High-risk group of asthma exacerbation
High-risk group meet any one of the following criteria:
1. Receiving systemic steroid administration, or immediately after the administration was discontinued.
2. History of hospitalization due to asthma attack in the past 1 year
3. Emergency visit due to asthma attack in the past 1 year
4. Tracheal intubation due to asthma attack in the past
5. Coexisting mental disorder
6. Noncompliance with asthma treatment plan
7. Not using an inhaled corticosteroid
8. Excessive use of short-acting β2 agonist
19
was normal. If 600 mg or more of sustained-release
theophylline is administered daily, serum theophyl-
line level is 8 μgmL or higher, or reduced clearance
is suspected, the dose of aminophylline should be re-
duced to half or less. If toxic symptoms of theophyl-
line (headache, nausea, vomiting, tachycardia, ar-
rhythmia, and others) occur during administration,
the intravenous infusion must be discontinued imme-
diately. Even if subjective symptoms are improved af-
ter intravenous infusion, patients should rest for
about 30 min. Serum levels of theophylline should be
monitored during treatment wherever possible.
Caution should be exercised for intoxication in the
presence of factors affecting theophylline clearance,
as shown in Table 18. For continuous administration
of aminophylline, one ampule (250 mg) of aminophyl-
line is added to 500 mL of maintenance infusion fluid
to be used in continuous intravenous drip infusion for
5 to 7 h (about 0.6-0.8 mgkgh) according to the in-
dividual’s physical constitution. The speed of intrave-
nous drip infusion should be adjusted to achieve 8 to
20 μgmL of serum theophylline levels. If toxic symp-
toms of theophylline occur during administration, the
intravenous drip infusion must be slowed down or
discontinued, and overdose should be ruled out by
measuring the level of theophylline. PaO2 may tran-
siently fall during continuous administration of
aminophylline, and when hypoxemia develops, oxy-
gen should be used (1-2 Lmin with nasal cannulas).
(4) Corticosteroids
Corticosteroids (steroids) are recommended for pa-
tients with exacerbated symptoms, insufficient bron-
chodilator action, moderate or severe exacerbations,
and for those who are already receiving steroids.90
The initial dose is set at 200 to 500 mg of hydrocorti-
sone or 40 to 125 mg of methylprednisolone,90 with
subsequent intravenous drip infusion of 100 to 200
mg of hydrocortisone or 40 to 80 mg of methylpredni-
solone every 4 to 6 h as needed. However, consider-
ing the time until clinical effects of steroids develop
(approximately 4 h) and safety, intravenous drip infu-
sion for about 30 to 60 min is recommended as initial
administration.
When symptoms become worse after the initial in-
fusion of hydrocortisone or methylprednisolone,
steroid-induced exacerbation should be considered
and the steroid should be changed to another hydro-
cortisone or another steroid (dexamethasone or be-
tamethasone). In patients with AIA, steroid phos-
phate esters (i.e., dexamethasone or betamethasone)
should be used because steroid succinate esters may
induce worsening in 40% to 60% of patients.91
Systemic steroid administration is indicated for pa-
tients with:
•moderate-to-severe exacerbations.
•history of a severe asthma attack requiring sys-
temic steroid administration.
•history of an advanced severe asthma attack requir-
ing hospitalization.
•significant risk factors of exacerbations (Table 19).
(5) Oxygen
Oxygenation can be initiated in patients with severe
dyspnea or PaO2 of less than 80 mmHg (SpO2, <95%)
with a target value of PaO2 of 80 mmHg or SpO2 of
about 95%. Hypoxemia can also be involved in the
contraction of the airway smooth muscle. Simultane-
ously, arrangements for endotracheal intubation and
ventilator should be made.
(6) Inhaled anticholinergics
Anticholinergics (ipratropium or oxitropium), added
to a β2-agonist during acute exacerbations, may en-
hance the bronchodilator effect to improve symptoms
and respiratory function92 and reduce hospitalization
rates.
(7) Other therapies
•Antibiotics are administered to patients with bacte-
rial infection accompanied by fever and purulent
sputum.
•Expectorants and mucolytic agents on sputum are
not essential.
•Analgesics are not generally used.
•Antihistamines have no immediate effects on acute
asthma symptoms.
•In fluid replacement, caution should be exercised
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Table　20　Treatment steps for asthma exacerbation
Treatment Home remedy, emergency visit and hospitalization, and ICU treatment†
Treatment step 1
Inhaled β2-agonist, as needed‡
Theophylline agent, as needed
Home remedy
Treatment step 2
Repeated inhalation of β2-agonist using a nebulizer§
Intravenous drip infusion of aminophylline¶
Intravenous drip infusion of steroid‖
Oxygen (1-2 L/min with nasal cannula)
Subcutaneous injection of Bosmin® (adrenaline, 0.1%)#
Consider anticholinergic inhalation.
Emergency visit
-  If symptoms improve within 1 h, the pa-
tient may be discharged.
- Insufficient response within 2-4 h
- No response within 1-2 h
Hospital admission: Switch to treatment 
step 3 as severe exacerbation.
Treatment step 3
Continuous drip infusion of aminophylline††
Repeated intravenous drip infusion of steroid‖
Oxygen (Target PaO2 is about 80 mmHg)
Subcutaneous injection of Bosmin® (adrenaline, 0.1%)#
Repeated inhalation of β2-agonist using a nebulizer§
Emergency visit
If no response within 1 h, hospitalization.
If exacerbated, switch to treatment for 
serious exacerbation.
Treatment step 4
Continue the above treatment.
If symptoms and respiratory function are exacerbated, con-
duct intubation.†
Despite oxygen inhalation, ≤50 mmHg PaO2 and/or rapidly 
elevated PaCO2 with impaired consciousness.
Mechanical ventilation†, Bronchial lavage
Consider general anesthesia (using isofl urane, sevofl urane, 
etc.).
Immediate hospitalization and ICU treat-
ment†
Aim of treatment: Elimination of dyspnea, normal movement, normal sleep, and normal everyday life. PEF rate is ≥80% of the predicted 
value or the best value. Oxygen saturation >95% (values after bronchodilator administration). No exacerbation of asthma symptoms by rou-
tine medication and inhalation.
Consider treatment step-up when the aim of treatment cannot be achieved within 1 hour.
†ICU or hospital rooms where tracheal intubation, assisted ventilation, bronchial lavage, etc., can be performed and continuous monitor-
ing can be conducted using a sphygmomanometer, electrocardiogram, and pulse oximeter. Since intubation and mechanical ventilation dur-
ing severe respiratory insufficiency are often threatening to life, they should be used by experienced specialists when inevitable in emergen-
cy.
‡Repeat 1-2 puffs of β2-agonist pMDI twice at an interval of 20 min. If ineffective or exacerbated, use 1 tablet of β2-agonist or 200 mg of
aminophylline.
§Inhalation of β2-agonist using a nebulizer: repeat every 20-30 min. Monitor the pulse to be maintained at ≤130/min.
¶Intravenous drip infusion of aminophylline (6 mg/kg) in 200-250 mL of isotonic fl uid: Administer the fi rst half for about 15 min and the re-
maining half for about 45 min. If toxic symptoms (headache, nausea, palpitation, extrasystole, etc.) occur, discontinue the infusion. When a
sufficient amount of theophylline was administered before exacerbation, reduce the dose of aminophylline to half or less. Routinely, mea-
sure serum theophylline levels in patients receiving it, wherever possible.
‖Intravenous drip infusion of steroids: intravenous drip infusion of 200-500 mg of hydrocortisone, 40-125 mg of methylprednisolone, or 
4-8 mg of dexamethasone or betamethasone. Subsequently, conduct intravenous drip infusion of 100-200 mg of hydrocortisone, or 40-80 
mg of methylprednisolone every 4-6 h as needed, or 4-8 mg of dexamethasone or betamethasone every 6 h as needed, or oral predniso-
lone (0.5 mg/kg/day). Steroid succinate esters (i.e., methyl prednisolone, prednisolone sodium succinate) should be avoided in patients who 
have or are suspected of having aspirin-induced asthma.
#Bosmin® (adrenaline, 0.1%): Bosmin® (0.1-0.3 mL) can be repeatedly administered at intervals of 20-30 min. Monitor the pulse to be 
maintained at ≤130/min. This agent is contraindicated in patients with ischemic heart disease, glaucoma (except for open-angle [simple] 
glaucoma), and hyperthyroidism. Sphygmomanometry and electrocardiography are required for patients with hypertension.
††Continuous intravenous infusion of aminophylline: following the fi rst intravenous infusion (see # above), conduct continuous intrave-
nous infusion of 250 mg of aminophylline (1 tube) for 5-7 h (about 0.6-0.8 mg/kg/h). Monitor serum theophylline levels to be maintained at
10-20 μg/mL (15-20 μg/mL to achieve the maximum effects). If toxic symptoms occur, discontinue the infusion.
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Table　21　
Exacerbation
intensity‡
Laboratory data†
PEF SpO2 PaO2 PaCO2
Wheezing/
chest tightness
Dyspnea when in a hurry
Dyspnea when in moving
Almost normal
≥80% Normal
Mild
(mild exacerbation)
Dyspnea but no trouble 
with lying down Slight dyspnea
Moderate
(moderate
exacerbation)
Dyspnea with trouble 
with lying down
Difficulty in
moving
Difficulty in
walking
60-80% >60 mmHg
Severe
(severe
exacerbation)
Dyspnea, cannot move
Abasia
Difficulty in
speaking
<60%
Serious
Respiratory attenuation
Cyanosis
Respiratory arrest
Immea-
surable
≤60 mmHg ≥45 mmHg
Anepia
Akinesia
Confusion
Impaired
consciousness
Incontinence
Dyspnea Movement
≤90%
<45 mmHg≥96%
<45 mmHg91-95%
≥45 mmHg≤60 mmHg≤90%
†Refer to values after bronchodilator administration.
‡Determine exacerbation grade based on the severity of dyspnea, referring to other items. If symptoms of different exacerbation intensi-
ties coexist, use more severe one.
Severity of an asthma attack and the corresponding treatment step
Treatment steps
in exacerbation
Treatment
step 1
Treatment
step 2
Treatment
step 3
Treatment
step 4
for dehydration, although substantial fluid replace-
ment is generally unnecessary.
4.2.2. Management at home
Since the severity of asthma symptoms vary widely
from mild wheezingchest tightness to severe attacks
showing abasia and speech difficulty, management of
acute exacerbations must be tailored according to
their severity, and patients must be informed about
the individualized approach. For this purpose, oral ex-
planation alone is not sufficient, and the patient
should be provided with a self-management plan (ac-
tion plan) with specific instructions for each condi-
tion.93 To treat wheezingchest tightness and moder-
ate asthma symptoms, 1 to 2 puffs of a SABA should
be administered using a pMDI. If the effects are in-
sufficient, inhalation should be repeated every 20 min
for 1 h and subsequently once an hour. At this time,
an oral β2-agonist or theophylline drug (aminophyl-
line) can be used at the same time.
Patients can be treated at home continuously when
these agents eliminate symptoms (80% of the pre-
dicted PEF rate or the best value) and their effect
continues for 3 to 4 h. However, if no therapeutic ef-
fect can be achieved, an oral corticosteroid (about 15-
30 mg of prednisolone) should be administered, and
the patient should refer to an emergency outpatient
unit immediately.
4.2.3. Treatment procedures in emergency out-
patients (Table 20)
Immediately on arrival, the severity of an asthma at-
tack should be determined. Asthma attack is roughly
classified according to the severity of symptoms as
follows: (i) mild: dyspnea but no difficulty in lying
down; (ii) moderate: difficulty in lying down and
walking; (iii) severe: difficulty in moving, abasia, and
speech difficulty; and (iv) serious symptoms: cyano-
sis, impaired consciousness, and respiratory arrest.
Treatment is classified into four treatment steps for
asthma exacerbations (Table 20). It is also important
to examine the history quickly and efficiently by
checking the points listed below; however, the initia-
tion of treatment should not be delayed.
•Time of onset and cause of exacerbations.
•Extent of exercise limitation and sleep disturbance.
•History of recent drug administration, names of
drugs and time of their last administration, and use
of steroids.
•Hospitalization and emergency visit due to asthma.
•History of respiratory failure and intubation due to
asthma.
•Cardiopulmonary diseases and complications.
•History of AIA and drug allergies.
After assessment of the severity of an asthma at-
tack, the treatment step is selected (Table 21).
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(1) Wheezingchest tightness, mild symptoms
(Mild exacerbations)
a) Assessment
Wheezing and chest tightness are felt during
breathing, but almost normal movements are main-
tained. The term “mild symptoms” indicates mild
dyspnea at rest, such that allows the patient to lie
down but causes mild difficulty with movement.
These symptoms do not affect daily activities. The ref-
erence value of the PEF rate is 80% and higher of the
predicted value or the best value (after bronchodila-
tor administration). A history of asthma and other dis-
eases should be taken in new patients. All patients
should be asked about treatments administered after
onset and should undergo a physical examination
such as chest auscultation. Patients with dyspnea pos-
sibly unrelated to asthma should be examined by ra-
diography and electrocardiogram.
b) Treatment
Administer step 1 treatment for asthma exacerba-
tions. Inhale a β2-agonist using a pMDI, DPI, or nebu-
lizer.
If symptoms disappear and conditions are stable
for 60 min without additional treatment, ensure that
there is no airway obstruction (80% %PEF) and dis-
charge the patient. If symptoms are not improved and
airway obstruction continues (80% %PEF), introduce
step 2 treatment.
(2) Moderate symptoms and continuous mild
symptoms (moderate exacerbation)
a) Assessment
Moderate asthma symptoms (i.e., dyspnea and or-
thopnea at rest, difficulty with movements). The PEF
rate is in the range of 60% to 80% of the predicted
value or the best value. When the patient is known to
have asthma, he or she should be examined for exac-
erbation as usual. The entire lungs should be exam-
ined for continuous rales and the presence of cyano-
sis. For a differential diagnosis of other diseases, vari-
ous examinations such as chest radiography, electro-
cardiogram, blood count, and arterial blood gas analy-
sis should be performed.
b) Treatment
Administer step 2 treatment for asthma exacerba-
tions.
(i) Administer an inhaled β2-agonist, 0.3 to 0.5 mL,
diluted in an appropriate volume of physiological sa-
line, using a nebulizer: repeat the inhalation every 20
to 30 min. The pulse should be maintained at a rate of
130min and lower. The use of a pMDI has the same
effects. If symptoms improve within 20 to 60 min and
are stable for 60 min after the last administration (%
PEF is 80%) and SpO2 is lower than 95%, the patient
may be discharged. If symptoms do not improve (%
PEF is 80%), the following treatments should be in-
itiated.
(ii) Intravenous infusion of aminophylline (250 mg
ampule) 6 mgkg in 200 to 250 mL of isotonic fluid:
administer the first half for about 15 min and the re-
maining half for about 45 min. If a sufficient amount
of theophylline had been administered before exacer-
bations, reduce the dose of aminophylline to half or
less. If toxic symptoms of theophylline (headache,
nausea, vomiting, tachycardia, arrhythmia, and oth-
ers) occur during infusion, immediately discontinue
the administration. Monitor serum theophylline lev-
els during treatment wherever possible.
(iii) Intravenous drip infusion of 200 to 500 mg of
hydrocortisone, 40 to 125 mg of methylprednisolone,
or 4 to 8 mg of dexamethasone or betamethasone:
systemic steroid administration should be initiated
immediately in patients with moderate or more se-
vere exacerbations, or patients who respond poorly to
the initial treatment with an inhaled β2-agonist. Ster-
oid administration should also be initiated immedi-
ately in patients who receive a high dose of an ICS
(equivalent to FP800 μgday) or receive an oral cor-
ticosteroid on regular basis, or who belong to a high-
risk group94 (Table 19). Steroid phosphate esters
(i.e., dexamethasone or betamethasone) should be
used in patients who have or are suspected of AIA.
Furthermore, about an hour of intravenous infusion
is recommended in patients with unconfirmed AIA, or
in patients who have received the agent for the first
time.
(iv) Oxygen: nasally administer oxygen at a dose of
1 to 2 Lmin to patients with severe dyspnea (PaO2,
80 mmHg).
(v) Subcutaneous injection of 0.1 to 0.3 mL of
adrenaline (0.1%): adrenaline can be repeatedly ad-
ministered at intervals of 20 to 30 min as needed, but
the pulse should be monitored and generally kept be-
low 130min. Adrenaline should be administered
carefully if dehydration and metabolic acidosis are
present. In addition, caution should be exercised for
agents such as halothane, antipsychotic, α blocker,
and catecholamine, the concomitant use of which is
contraindicated. Adrenaline is generally contraindi-
cated in patients with complications, such as arterio-
sclerosis, hyperthyroidism, glaucoma (except for
open-angle [simple] glaucoma), diabetes mellitus, se-
rious arrhythmia, and psychoneurosis, but if must be
used, it should be administered with care. The use of
adrenaline is preferably avoided in pregnant women.
Hypoxemic patients are at high risk for adverse ef-
fects.
(vi) Inhaled anticholinergics: anticholinergics can
be administered additionally to β2-agonist because of
their additive effect.
c) Action plan after treatment
(i) Favorable response: when wheezing and dysp-
nea are absent for 1 h (%PEF, 80%; SpO2, >95%), dis-
charge the patient and step up the long-term treat-
ment. Subsequently, apply medications for long-term
management according to an appropriate treatment
Adult Asthma
Allergology International Vol 63, No3, 2014 www.jsaweb.jp 315
Table　22　Conditions requiring tracheal intubation
- Severe ventilatory impairment or cardiac or respiratory 
arrest
- Marked respiratory muscle fatigue
- <50 mmHg PaO2 even after maximum oxygenation
- ≥5 mmHg/h elevation in PaCO2
- Marked elevation in PaCO2 and consciousness disorder
step of asthma. In patients receiving an oral steroid,
consider adding or increasing the dose of corticoster-
oid for 1 to 2 weeks.
(ii) Insufficient response: mild wheezing and con-
tinued dyspnea (<80% %PEF, 95% SpO2). Step up to
step 3 treatment (see the next chapter), but if symp-
toms do not improve within 2 to 4 h, consider hospi-
talization.
(iii) No response: marked extensive wheezing and
dyspnea (orthopnea) (%PEF,70%) persist. Step up to
step 3 treatment, but if symptoms do not improve
within 1 to 2 h after addition of intravenous steroids,
consider hospitalization.
(iv) After hospitalization: continue step 3 treatment
both in the case of b) and c).
(3) Severe symptoms (severe exacerbations) or
continued moderate symptoms
a) Assessment
If the patient with asthma symptoms presents at an
emergency department, briefly check the physical
findings to determine the severity and differentiate
the findings from other diseases that cause dyspnea.
Subsequently, ask short relevant questions about the
causes of exacerbation and previous treatment.
(i) Symptoms and physical findings: patients with
serious symptoms adopt a hunched position and can-
not move because of dyspnea. They may suffer from
speech difficulty, confusion, or unconsciousness. Ac-
cessory respiratory muscles are used for breathing,
with the suprasternal space depressed. Usually,
marked wheezing is heard in the chest. Attenuation
or elimination of breath sounds indicates respiratory
arrest or its signs, but cyanosis is usually absent.
(ii) Tests: generally, spirometry cannot be per-
formed. If possible, the PEF is less than 60% of the
predicted value or the best value. Blood gas analysis
is more reliable to determine severity. Severe airway
obstruction is indicated at SpO2 of 90% and lower, and
PaCO2 in the range of 45 mmHg to 60 mmHg. Dysp-
nea due to other causes is differentiated from asthma
using blood count, chest radiography, electrocardio-
gram, and other tests.
b) Treatment
Initiate step 2 treatment, followed by step 3 as con-
tinuous treatment.
(i) Initial treatment: in patients with serious symp-
toms, who cannot move and have speech difficulty,
establish venous access immediately, initiate treat-
ment with an inhaled β2-agonist using a nebulizer,
and administer adrenaline (0.1%), aminophylline, and
steroids according to step 2 treatment.
•Administer from 0.3 to 0.5 mL of an inhaled β2-
agonist, diluted in physiological saline, using a
nebulizer.
•Intravenous drip infusion of aminophylline (250
mgampule) 6 mgkg in 200 to 250 mL of isotonic
fluid. Administer the first half for about 15 min and
the remaining half for about 45 min. When a suffi-
cient amount of theophylline had been adminis-
tered before exacerbations, reduce the dose of
aminophylline to half or less.
•Intravenous drip infusion of 200 to 500 mg of hy-
drocortisone or 40 to 125 mg of methylpredniso-
lone or 4 to 8 mg of dexamethasone or betametha-
sone. Steroid phosphate esters (i.e., dexametha-
sone or betamethasone) should be used in patients
who have or are suspected of having AIA. In addi-
tion, intravenous drip infusion spending for about
one hour is recommended for patients, in whom
the presence or absence of AIA is unknown, or
who receive the agent for the first time.
•Subcutaneous injection of 0.1 to 0.3 mL of adrena-
line (0.1%). Subcutaneous injection of adrenaline
(0.1%) can be repeated at intervals of 20 to 30 min
as needed. The pulse should be monitored and
generally kept below 130min. The patient should
be carefully monitored for the presence of the
above contraindications.
•Oxygen. Target PaO2 in oxygenation is around 80
mmHg. Caution should be exercised for CO2 nar-
cosis in patients complicated by COPD. In poorly
responsive patients, check that consciousness is
normal and introduce noninvasive positive pres-
sure ventilation (NPPV), intubation, mechanical
ventilation, and others, immediately depending on
the patient’s status. NPPV improves the patient’s
breathing pattern through pressure support venti-
lation and avoidance of airway collapse at the end-
expiration phase by positive end-expiratory pres-
sure (PEEP), and thus may be effective in terminat-
ing the vicious circle during acute asthma attack.95
Consider hospitalization (immediately hospitalize
patients if no improvement is noted within 1 h after
treatment).
(ii) Continuous treatment: continue step 3 treat-
ment.
•Continuous intravenous drip infusion of aminophyl-
line at a dose of 0.6 to 0.8 mgkgh. Target serum
level of aminophylline is 8 to 20 μgmL. If symp-
toms that suggest intoxication develop, immedi-
ately slow down or discontinue the administration
to examine overdose by measuring the theophyl-
line level. Consider various factors affecting the se-
rum theophylline level (Table 18).
•Intravenous drip infusion of 100 to 200 mg of hy-
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Table　 　Conditions requiring hospitalization
- Moderate symptoms (60-80% %PEF), insufficiently responsive to 2- to 4-h treatment (≤70% %PEF) or nonresponsive to 1- to 
2-h treatment
- Severe symptoms (<60% %PEF) nonresponsive to treatment within 1 h
- History of severe asthma attack requiring hospitalization
- Chronic symptoms that had continued for a long period (several days to 1 week) until emergency visit
- Mental disorders or communication difficulties
23
- Complications, such as pneumonia, atelectasis, and pneumothorax
- Difficulties in consulting a medical institution, e.g., heavy traffic when returning home
Table　24　Conditions for admission to ICU
- No response to initial treatment in an emergency room
- Symptoms suggesting risks of confusion, respiratory arrest, 
and unconsciousness
- Imminent respiratory arrest: ≥45 mmHg PaCO2 continues 
(however, respiratory insufficiency may occur regardless of 
PaCO2 level)
drocortisone or 40 to 80 mg of methylprednisolone
every 4 to 6 h as needed. Alternatively, intravenous
infusion of 4 to 8 mg of dexamethasone or be-
tamethasone every 6 h as needed. Alternatively,
oral prednisolone (0.5 mgkg, 20-30 mgday). Ad-
ditional intravenous drip infusion of 100 to 200 mg
of hydrocortisone, or 40 to 80 mg of methylpredni-
solone every 4 to 6 h as needed, or 4 to 8 mg of
dexamethasone or betamethasone every 6 h as
needed. Steroid phosphate esters (i.e., dexametha-
sone or betamethasone) should be selected in pa-
tients who have or are suspected of having AIA. In
addition, spending about an hour for the intrave-
nous drip infusion is recommended when the pres-
ence of AIA is not confirmed, or the steroid has
been administered for the first time. Since hydro-
cortisone causes edema when administered for 3
days or longer, switch to a different steroid if ster-
oid administration has to be continued after 3 days.
As an oral drug, administer an oral prednisolone
(approximately 0.5 mgkg, 20-30 mgday) once in
the morning, and, after remission, discontinue the
administration within 7 to 14 days or reduce it to
the usual dose before attacks. There is no benefit
from tapering the dose of an oral corticosteroid af-
ter remission, and the administration may be dis-
continued abruptly.96 Initiate the administration of
an ICS when inhalation becomes possible during
the course of treatment.
•Oxygen. Continuously administer an optimal dose.
(4) Serious asthma symptoms and emergency
(serious exacerbations)
a) Assessment
Emergency care is indicated (e.g., endotracheal in-
tubation and mechanical ventilation), when clinically
severe ventilatory impairment or respiratory arrest
occurs, when there is no response to the above treat-
ments, when PaO2 is less than 50 mmHg even after
maximum oxygenation andor rapid increase of
PaCO2 with impaired consciousness occurs, or when
PaCO2 has been rapidly increasing to 5 mmHg and
higher an hour. If PaCO2 exceeds 45 mmHg, prepare
intubation for mechanical ventilation. The cases that
require endotracheal intubation are presented in Ta-
ble 22. Since intubation is associated with a consider-
able risk, an experienced specialist should be con-
sulted wherever possible. NPPV may improve the pa-
tient’s breathing pattern through pressure support
ventilation and prevent airway collapse at the end-
expiration phase by PEEP (treatment by an experi-
enced specialist is desirable). Note that initiation of
intubation or mechanical ventilation is not delayed,
especially in the case of disturbed consciousness or
hypersecretion.
b) Treatment
Administer step 4 treatment.
(i) Endotracheal intubation and artificial respira-
tory management97: conduct endotracheal intubation
according to the routine procedure. Immediately con-
nect the endotracheal tube to a volume-cycled ventila-
tor. Adjust the ventilator with 100% fraction of in-
spired oxygen (FIO2), 5 to 8 mLkg tidal volume. Set
the ratio of inspiratory-to-expiratory phases at 1 : 3 or
above and equalize the duration of each phase. Keep
the airway pressure below 50 cm H2O (maximum)
and from 21 to 25 cm H2O (average). Subsequently,
set FIO2 at about 80 mmHg PaO2. Here, ensure the
maintenance of PaO2 and the prevention of baro-
trauma even if PaCO2 values are high, until exacerba-
tions improve. In severe exacerbations, the airway
pressure at the end of expiration is often elevated and
airway is under the auto-PEEP condition. As auto-
PEEP is often caused by central airway obstruction, it
is reported that PEEP by mechanical ventilation may
be effective to cancel the auto-PEEP. However, in
principle, avoid using a ventilator at high PEEP, con-
sidering the risk of barotrauma. Intubation should
preferably be as short as possible.
(ii) Treatment for exacerbation: immediately after
intubation, 0.3 to 1.0 mL of a β2-agonist or adrenaline
(0.1% before dilution), both diluted 10-fold in physi-
ological saline can be administered through an en-
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Table　25　Conditions for allowing a patient to go home from an emergency room
- Identify and avoid the causes of exacerbation.
- Consult a physician as soon as possible after going home. Inform that continuous outpatient treatment is required until PEF re-
turns to around the best value. In addition, examine the appropriateness of daily long-term treatment.
- Prescribe agents for 3-5 days when the patient goes home. Optionally, oral corticosteroids, as well as bronchodilators, are of-
ten needed.
- Check whether a patient has no trouble inhaling an inhalant or using a PEF meter adequately.
- Check whether a patient or his/her family has any problem with measures against exacerbation. It is particularly important to 
explain medicines and self-management in detail, to recognize the signs of exacerbation, immediately initiate treatment, and 
visit a medical institution.
Table　26　Conditions for discharge
- No need of inhaling a bronchodilator at ≤4-h intervals
- No short breath in walking
- No wake-up due to exacerbation at night or in the early 
morning
- (Almost) N  ndings
- PEF or FEV1 is ≥80% of predicted values. Diurnal variation 
is <20%.
- Normal PaO2 value
- No trouble handling an inhaler. No trouble handling a spac-
er
- Appropriate actions against exacerbation.
- Patients understand conditions for discharge and prescrip-
tion.
- Creation of a treatment plan after discharge
dotracheal tube. Initiate and continue systemic phar-
macotherapy in the same manner as for severe
asthma symptoms. For symptoms refractory to phar-
macotherapy, general anesthesia using a narcotic
agent (isoflurane, sevoflurane, and others) with a
bronchodilator action is effective in airway relaxation.
Of note, the use of halothane should be avoided be-
cause it may cause ventricular arrhythmia when used
simultaneously with β2-agonists or aminophylline.
(iii) Conditions for discontinuation: extubate the
patient when consciousness is restored and maxi-
mum airway pressure is reduced to 20 cm H2O or be-
low by spontaneous respiration without assisted res-
piration.
4.2.4. Indications for hospitalization
Consider hospitalizing a patient with symptoms that
are not improved within several hours after the initia-
tion of treatment (Table 23). Immediately hospitalize
a patient with serious symptoms to conduct a more
potent treatment.
4.2.5. Indications for intensive care unit admis-
sion
Consider asthma treatment in an intensive care unit
or consult a specialist experienced in asthma treat-
ment in the situations presented in Table 24.
4.2.6. Indications for discharge from an emer-
gency room
Airway obstruction remits and PEF recovers to 80%
and higher of the predicted value or the best value.
The patient may be discharged if symptoms are sta-
ble for 60 min or longer after the last use of a bron-
chodilator. Conditions that must be met to discharge
a patient from an emergency room are shown in Ta-
ble 25.
4.2.7. Indications for discharge from the hospital
It is important to educate patients who experienced
severe exacerbations requiring hospitalization about
the high risk of death from asthma and to provide
consistent instructions after discharge. Patients with
repeated exacerbations should receive adequate
treatment that considers psychological and social fac-
tors. It is necessary to check that symptoms have not
exacerbated for 12 or 24 h or longer after treatment
before discharge from the hospital (Table 26).
5. Indications for a Referral to a Specialist
Asthma is a complex disease caused by various exter-
nal and physical factors. When the diagnosis or long-
term treatment is challenging, the patient should be
referred to a specialist based on cooperation system
between hospitals and clinics.
6. Specific Considerations
6.1. Aspirin-Induced Asthma
6.1.1. Definition
AIA is not induced via IgE antibodies, so AIA is not al-
lergic reaction against aspirin. NSAIDs, especially
arachidonate cyclooxygenase-1 (COX-1) inhibitors,
such as aspirin, induce strong symptoms in the air-
ways, including nasal congestion, nasal discharge,
and asthma attack. As the inhibitory effects of
NSAIDs on the COX activity are much higher, asth-
matic reaction appears to be stronger. Because COX-
2 inhibitors such as cerecoxib can be used safely in
patients with AIA, this reaction is due to the inhibi-
tion of COX-1. AIA is also known as “aspirin-
intolerant asthma”; however, recently, it has been
termed “aspirin-exacerbated respiratory disease” be-
cause it also induces symptoms in the upper respira-
tory tract.98
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6.1.2. Epidemiology, clinical aspect, and symp-
toms
About 5% to 10% of the patients with adult asthma
have AIA, and the ratio of men to women is 1 : 2. AIA
usually develops in 20- to 40-year-old individuals, and
is characterized by weak or no atopy.99 Half of these
individuals are severe asthmatics and often have
fixed airflow obstruction. When the attack in AIA is
caused by the administration of COX inhibitors, wa-
tery rhinorrhea and nasal congestion often develop as
prodromal symptoms that may be accompanied by fa-
cial flushing, conjunctival hyperemia, and digestive
symptoms (abdominal pain, diarrhea, and others).
Sometimes, chest pain, itching, and urticarial may oc-
cur simultaneously. Patients with AIA often have
eosinophilic rhinitis with a nasal polyp and distorted
sense of smell. Similarly, more than half of asthmatic
patients with a nasal polyp have AIA. Nasal symp-
toms, especially distorted sense of smell, are ob-
served several years prior to the onset of asthma
symptoms. More than 50% of the patients have
eosinophilic otitis media, about 30% have symptoms
of eosinophilic colitis, and about 10% to 20% have vari-
ant angina pectoris.
6.1.3. Pathogenesis
The pathogenesis of AIA is thought to be the overpro-
duction of CysLTs.100 Urinary LTE4 concentrations is
several times higher in stable patients with AIA com-
pared with individuals without AIA, and when AIA at-
tack occurs, LTE4 levels are more than several times
higher compared with the stable condition.
6.1.4. Diagnosis
Because of its nonallergic mechanisms, AIA cannot
be diagnosed with general tests for allergies. To diag-
nose AIA, a medical interview and challenge test are
required. In a medical interview, a physician should
ask about the side effects of NSAIDs, disturbances in
the sense of smell, and the presence of a nasal polyp
and sinusitis. In addition, AIA can be diagnosed if
asthmatic patients fulfill more than two of the follow-
ing criteria: moderate-to-severe asthma, asthma onset
after early adolescence, weak or no atopy, symptoms
of refractory cough, or eosinophil count in the periph-
eral blood exceeding 10%. To confirm the diagnosis, it
is recommended to perform a challenge test for
NSAIDs, preferably in a specialist center with experi-
enced experts.
6.1.5. Management of fever and pain in patients
with AIA
Oral acetaminophen is considered to be safe com-
pared with regular NSAIDs. It has been reported that
in 34% of asthmatic patients the pulmonary function
worsens at a dose of 1000 to 1500 mg of aceta-
minophen; therefore, it is safe to administer less than
500 mg of acetaminophen (or preferably even less
than 300 mg) in patients with AIA.101 A selective
COX-2 inhibitor, cerecoxib, has a high safety profile
but it rarely induces an asthma attack in unstable pa-
tients with severe asthma.
6.1.6. Management of aspirin-induced attack of
asthma
The management of an asthma attack induced by
NSAIDs is basically similar to the ordinary treatment
for exacerbations, but the following three issues
should also be taken into consideration.
(1) Succinic esters of steroids often induce a se-
vere asthma attack (sometimes fatal) if administered
rapidly. In patients with severe asthma, the severity
of an asthma attack is higher. A high dose of these
agents, if administered rapidly, may induce a severe
attack. Most of the patients with AIA are potentially
hyperresponsive to succinic ester of steroids. Phos-
phate esters of steroids themselves do not affect AIA,
but some additives could cause worsening of exacer-
bations. Therefore, a rapid intravenous administra-
tion of these agents is not safe, even in intramuscu-
larly. A rapid intravenous administration of these
agents is contraindicated, and they should be admin-
istered slowly for more than 1 to 2 hours.
(2) Inhalation of bromhexine hydrochloride salt is
known to induce an aspirin-induced attack of asthma,
while oral administration is known to be safe.
(3) Adrenaline (0.1%) is useful in the treatment of
aspirin-induced attacks of asthma. A low dose of
adrenaline (0.1-0.2 ml) should be used for AIA and re-
peated administration is possible.
6.1.7. Long-term management of aspirin-induced
asthma, prevention of nonsteroid anti-inflamm-
atory drug use, and desensitization of aspirin
Long-term management of AIA is basically similar to
that of asthma without AIA. Because CysLTs are in-
volved in the pathogenesis of AIA, LTRAs in combina-
tion with ICSs are a better choice for long-term man-
agement.101 LTRAs can improve both the symptoms
of asthma and nasal sinusitis and can significantly im-
prove, although not completely, the reaction of AIA.
Treatment for chronic sinusitis and nasal polyp is im-
portant to stabilize AIA. A severe nasal polyp should
be removed by endoscopic surgery.
6.2. Exercise-Induced Asthma
6.2.1. Pathogenesis and mechanism of exercise-
induced asthma
Asthma attack or transient bronchoconstriction sev-
eral minutes after exercise is called “exercise-induced
asthma” or exercise-induced bronchospasm. EIA is
often induced by a relatively intensive exercise up to
80% of the maximum heart beats for 3 to 8 minutes.102
Exercise-induced attack of asthma may be induced by
occasional swimming, running (especially short- or
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intermediate-distance splint), and inhalation of cold
and dry air.
6.2.2. Prevention of exercise-induced asthma
Inhaled β2-stimulants are superior to other asthma
drugs owing to their bronchodilatory action; they pre-
vent bronchoconstriction induced by EIA. LTRAs are
also useful and comparable or superior to LABAs for
the prevention of EIA. EIA should be prevented by
long-term management with controller drugs and in-
halation of β2-stimulants before exercise.
6.2.3 Management of asthma in athletes
(1) Pathogenesis of asthma in athletes
The prevalence of asthma in athletes is higher than
that in nonathletes. The pathogenesis of asthma in
this group is associated not only with the general
mechanisms including the cooling of airways or
change of osmotic pressure, but also with some spe-
cific mechanism. Hard exercise associated with ex-
cessive ventilation of up to 200 Lmin induces the
stretching of the airway epithelial cells and causes tis-
sue damage and repair in the airways,103 resulting in
airway hyperresponsiveness and remodeling.
(2) Diagnosis of asthma in athletes
When athletes participate in international or domestic
athletic competitions, they should undergo an objec-
tive diagnose of asthma. If they are treated with
asthma drugs that are prohibited owing to their dop-
ing effect, they have to present a medical certificate
issued by a physician and apply for a Therapeutic Use
Exemption (TUE).
(3) Treatment and management of asthma in ath-
letes
Because a number of asthma drugs is prohibited by
the World Anti-Doping Agency, a physician should be
careful about the use of asthma drugs in athletes. An
application for TUE is needed when the use of
asthma drugs is required, and asthma should be diag-
nosed on the basis of objective findings. Although
long-term management and treatment of asthma ex-
acerbations in athletes is similar to those in general
asthmatic patients, a number of asthma drugs is pro-
hibited in athletes. Drugs that are permitted include
ICSs, LTRAs, oral theophylline, salmeterol, and for-
moterol, while the list of prohibited drugs includes
patch formulation of tulobuterol and all oral β2-
stimulants. As concerns relievers, salbutamol is per-
mitted at a dose of up to 1600 μgday without the
need to apply for TUE. When asthma is controlled by
an inhalation of BUD plus formoterol, a maximum
dose of 36 μg of formoterol daily (8 inhalationsday)
is permitted. Systemic oral or intravenous corticoster-
oids need to be administered retroactively before
scheduled athletic competition.
(4) Prevention of asthma in athletes
To prevent exercise-induced attack of asthma, ath-
letes need to be treated with SABAs 10 to 15 min
prior to exercise. If asthma symptoms are intense, an
LTRA is administered in combination with ICSs as
controllers. Airway hyperresponsiveness improves or
resolves after athletes stop intensive training for a
competition.
6.3. Elderly Patients with Asthma
According to the World Health Organization’s defini-
tion of elderly persons, asthmatic patients older than
65 years may be defined as elderly. Because elderly
adults vary considerably in senescent changes re-
lated to aging and have comorbidities, the patho-
physiology of asthma in this patient group is more
complicated compared with younger asthmatic pa-
tients. Sometimes, the diagnosis of asthma is difficult
because of senescent changes. In 2012, 1874 patients
were reported to die of asthma, of whom 90% were
older than 65 years. To reduce mortality from
asthma, it is important to prevent death as well as to
properly diagnose and manage asthma in elderly pa-
tients.
6.3.1. Diagnosis
Asthma symptoms in elderly persons are similar to
those in younger patients. However, in elderly pa-
tients with asthma in remission, the symptoms and
pulmonary function are not as stable as in younger
patients. Because elderly patients are insensitive to
the sensation of dyspnea from bronchoconstriction,
the degree of severity is sometimes underestimated.
The diagnosis of asthma may be difficult in the case
of a mild disease or the presence of comorbidities.
Sometimes, it may be difficult to recognize the clini-
cal picture of asthma because elderly patients often
have COPD, heart failure, and reflux esophagitis. To
diagnose asthma in an elderly person, lung cancer,
and lung tuberculosis along with its sequelae have to
be excluded. The measurement of brain natriuretic
peptide is useful to distinguish asthma from heart fail-
ure. Chest radiograph and echocardiography are also
useful in a differential diagnosis.
6.3.2. Treatment
When introducing treatment in elderly patients with
asthma, complications such as COPD, effectiveness
of asthma drugs, adherence to drug regimen, and ap-
proach to the use of inhaler should be considered. A
physician should be careful about asthma exacerba-
tions induced by NSAIDs used for arthritis and β-
blockers used for hypertension and glaucoma.
(1) Chronic obstructive pulmonary disease
COPD is a significant coexisting disease that should
be included in a differential diagnosis in elderly pa-
tients with asthma. The pathophysiological features
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of asthma are eosinophil-predominant inflammation
from the central to peripheral airway and reversible
airway obstruction. On the other hand, in COPD,
neutrophil-predominant inflammation and structural
alterations, located in the peripheral airway and alveo-
lar capillary vessels are observed. Moreover, in
COPD, airway obstruction is caused by a combina-
tion of peripheral airway and emphysematous lesions.
Thus, a differential diagnosis based on clinical symp-
toms is often difficult, although the diseases differ in
their pathophysiological characteristics. According to
some reports, 18.4% to 31.7% of elderly patients aged
65 years and over actually have both diseases. A pre-
vious epidemiological report showed that more than
half of the elderly patients with obstructive pulmo-
nary disease had asthma-COPD overlap syndrome
(ACOS).104 Because patients with overlap syndrome
are reported to have a rapidly decline in the pulmo-
nary function, an ICS or a combination of an ICS and
inhaled LABA is recommended in the early stage of
the disease, in addition to long-acting bronchodila-
tors, which are mainly used in patients with COPD.105
To treat airway obstruction in patients with overlap
syndrome, LAMA and theophylline are used.
(2) Dementia
A physician should carefully evaluate adherence to
the treatment regimen and technique of inhalation in
patients with dementia. In such cases, health care
personnel may be needed to support and instruct pa-
tients in the use of asthma drugs including inhaled
agents.
(3) Cranial nerve disease; disease of motor or-
gans
Health care personnel may be needed to support and
instruct patients with cranial nerve disease and dis-
ease of motor organs in the use of asthma drugs.
6.3.3. Asthma drugs
(1) Corticosteroids
In elderly patients with asthma, oral corticosteroids
may cause neurological symptoms including excita-
tion or confusion. ICSs are the first-choice drugs be-
cause they do not cause systemic side effects even in
elderly patients. It is important for elderly patients to
repeatedly check their technique of inhalation and re-
ceive proper instruction on how to use inhaled drugs
because various types of devices for inhaled drugs
are developed. When elderly patients are unable to
use a dry-powder inhaler, it is sometimes useful to
change to a pMDI, use spacer of inhaled drugs or
change to suspension of corticosteroids by jet nebu-
lizer. Long-term treatment with high-doses of ICSs
(equivalent dose of 800 μg of FP per day) may cause
systemic side effects including progression of osteo-
porosis, glucose metabolism, change of estrogen lev-
els, hypertension, peptic ulcer, or immunosuppres-
sion. Female elderly patients are particularly suscepti-
ble to progression of osteoporosis and bone fracture.
(2) Bronchodilators
Bronchodilators such as SABAs and LABAs with
ICSs are used in elderly patients, but their effective-
ness is lower than that in younger patients. The effec-
tiveness and side effects of these drugs should be
carefully evaluated in elderly patients. LAMAs are
relatively useful in patients with coexisting COPD or
in those who are less responsive to β2-stimulants. A
LAMA is used with other asthma drugs such as ICSs
or in combination with ICSs and inhaled LABAs. A
LAMA needs to be administered by paying thorough
attention to its influence on glaucoma (eye ball pres-
sure) and anuresis (difficulty in urination) by benign
prostatic hypertrophy. Because the effectiveness of
inhaled LABAs in chronic asthma exacerbations does
not differ from that of oral asthma drugs, oral drugs
are frequently used in elderly patients. Patch formula-
tion of tulobuterol is also useful in this patient group.
The side effects of β2-stimulants affecting the cardio-
vascular tend to be more common in elderly than in
younger patients. Because β2-stimulants often cause
tremor and tachycardia, a single-dose inhalation of β2-
stimulants is recommended in elderly patients with
cardiovascular disease.
(3) Theophylline
Theophylline levels in the peripheral blood should be
maintained at 5 to 10 μgml, and concomitant use
with other asthma drugs is recommended. A physi-
cian should monitor blood theophylline levels be-
cause the side effects in the case of drug overdose
may be severe and even fatal in elderly patients. Con-
comitant use of theophylline with other asthma drugs
is expected to improve the pulmonary function and
QOL.
(4) Leukotriene receptor antagonist
LTRAs are effective for asthma treatment in elderly
patients and is associated with a low risk of side ef-
fects.
(5) Antiallergic drugs
Antiallergic drugs are not effective in elderly patients
because most of these patients have nonatopic
asthma. Patients should be monitored for side effects
because antiallergic drugs have low clearance.
6.4. Asthma in Early Adolescence or Early Twen-
ties
6.4.1. Characteristics
The characteristics of asthma in patients in early ado-
lescence or early twenties are listed below.
•If asthma has not been successfully controlled until
this age, it often continues into adulthood (adult
asthma).
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•Mortality from asthma increases in this period
compared with childhood.
•Patients and their parents tend to be discharged
rapidly.
•These patients may have a lower quality of life ow-
ing to physical and emotional distress that affects
their relationships as well as educational and work
opportunities.
•Adherence to treatment regimen is often worse.
•A higher rate of asthma is observed in patients of
this age with anxiety disorder and depression.
•The rate of medical consultations is significantly
lower.
•Asthma attack is affected by menses.
•There is a relatively high risk of air leak syndrome
such as mediastinal pneumothorax and subcutane-
ous emphysema.
•Patients often have atopic asthma despite a de-
crease in IgE levels.
6.4.2. Lack of adequate asthma control
The reasons why asthma control is inadequate in this
patient group are listed below.
•Worse adherence to treatment regimen.
•The rate of medical consultations is significantly
lower.
•Insufficient recognition of alterations in the patho-
physiology of asthma.
•Inappropriate transition from pediatric to internal
medicine care.
•Transition to single life.
6.4.3. Treatment considerations
A physician should treat asthmatic patients in early
adolescence or early twenties with the awareness that
these patients are incapable of self-management.
These patients require a treatment plan and educa-
tion in the management of asthma, but also specific
problems typical for this patient group as listed in
sections 6.4.1. and 6.4.2. should be addressed. When
a physician introduces the patient to the asthma treat-
ment plan, it is sometimes preferable that the patient
alone takes part in the plan rather than with the assis-
tance of his or her parents. It may be useful for the
teaching staff to become involved in the treatment
plan to avoid exposure to allergens and prevent EIA.
It is necessary to make sure that patients with unsta-
ble asthma adhere to the treatment regimen.
6.5. Pregnancy
6.5.1. Influence of bronchial asthma on preg-
nancy and birth
The number of pregnant women with asthma tends to
increase. Because functional residual capacity in
pregnant women decreases even in normal preg-
nancy, an asthma attack accompanied by airway ob-
struction tends to cause hypoxemia in the fetus, pos-
ing risks of miscarriage, increased prematurity, and
brain disorders.106 In fact, premature delivery, low
birth weight, and malformation are more common
among patients with asthma. However, appropriate
management of asthma can efficiently reduce the risk
of death of the mother and fetus. Asthma causes no
severe exacerbations when well controlled before de-
livery. In addition, asthma symptoms and airway hy-
perresponsiveness improve in late gestation, espe-
cially at 37 to 40 weeks. After birth, asthma status and
airway hypersensitivity will be almost the same as be-
fore pregnancy.107
6.5.2. Effect of antiasthmatic drugs on preg-
nancy and birth
There is little evidence of teratogenicity for most an-
tiasthmatic drugs (Table 27). There have been no re-
ports associating the cleft palate and systemic high-
dose steroid administration in humans. Since steroids
do not readily pass through the placenta, their serum
levels in fetuses are much lower than those in moth-
ers, thus reducing the risk of adrenal suppression. To
gain control of severe asthma, which causes fetal hy-
poxia and harms the mother’s health, do not hesitate
to administer a systemic steroid, although too long
administration should be avoided wherever possible.
ICSs are highly safe for the mother and fetus. Accord-
ing to the FDA, all asthma drugs are categorized into
five classes based on safety (where A is the safest and
E is the least safe). BUD (dry powder) is safe and is
ranked in category B. Other ICSs are categorized as
class C. On the other hand, ICSs are not classified in
the National Asthma Education Prevention Program,
and they are all recommended as the first-choice
drugs in patient requiring step 2 treatment, even dur-
ing pregnancy and breast feeding. There are no re-
ports on teratogenicity of either inhaled or oral β2-
agonist, tulobuterol, and it is considered safe during
pregnancy. Since a patch-type β2-agonist is still a new
drug form, introduced to the market only in Japan
and South Korea, there is no evidence of its safety
when used during pregnancy. However, patches are
regarded as safe, since oral and inhaled forms (not on
the market now) of tulobuterol are considered safe.
There have been no reports on the teratogenicity of
either oral or intravenous theophylline, suggesting its
usefulness in controlling asthma during pregnancy.
Since degradative rate of theophylline in the infant is
slow, caution should be exercised in administering it
to infants during lactation. Of allergy drugs, DSCG is
considered safe. Since there is not enough evidence
for the safety of LTRAs in humans, they should be ad-
ministered during pregnancy only when the advan-
tages outweigh the disadvantages. There seems to be
little teratogenicity for classic antihistamines and rela-
tively early-generation antiallergic drugs (epinastine,
emedastine, ketotifen, tazanolast, pemirolast, azela-
stine, tranilast, and others). However, they should be
administered during pregnancy only when the advan-
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Table　27　Agents that can be used for asthma during pregnancy and precautions for their use
Inhalants
1. Inhaled corticosteroid†
2. Inhaled β2 agonist (including a combination inhaler with an inhaled corticosteroid)‡
3. Disodium cromoglycate (DSCG)
4. Inhaled anticholinergic§
Oral medicine
1. Theophylline sustained-release preparation
2. Oral β2 agonist
3. Oral corticosteroid¶
4. Leukotriene receptor antagonist‖
5. Antihistamine‖
Injections
1. Steroid¶
2. Aminophylline
3. Adrenaline (0.1%)#
Others
Patch-type β2 agonist: Tulobuterol††
†Safety of budesonide in humans has been demonstrated in great detail.
‡There is less evidence of the safety of long-acting inhaled β2 agonist (LABA) than those of short-acting inhaled β2 agonist (SABA). 
However, these agents are almost comparable in their safety during pregnancy.
§There is no evidence of safety as a long-term management agent used during pregnancy. Safety as a reliever agent has been 
demonstrated.
¶Prednisolone and methylprednisolone do not appreciably pass through the placenta.
‖Can be administered during pregnancy only when the advantages outweigh the disadvantages. Have few risks even if unknowingly ad-
ministered during pregnancy.
#Use the subcutaneous injection of adrenaline only when inevitable. Generally avoid injection to pregnant women.
††Safe as an inhalant or oral medicine. More evidences are required.
tages outweigh the disadvantages.
6.5.3. Asthma treatment during pregnancy
Considering the risks of an asthma attack on fetuses
and pregnant women, it is more beneficial to continue
treating patients with asthma during pregnancy. Ap-
propriate measures (agents, allergen avoidance, envi-
ronmental management, smoking cessation and sepa-
ration of smoking areas, rest of mind and body, and
others) should be taken against exacerbating factors
to prevent symptoms and maintain respiratory func-
tion. ICSs are recommended as first-line therapy for
long-term management. If an ICS alone is not effec-
tive enough, add a LABA, sustained-release theophyl-
line, patch-type β2-agonist, and others. Consider
LTRAs only when the advantages outweigh the disad-
vantages (Table 27).
Allergen-specific immunotherapy (hyposensitiza-
tion) can be continued during pregnancy if initiated
before pregnancy. However, do not initiate the ther-
apy during pregnancy. Continue the administration of
anti-IgE antibody only when the advantages outweigh
the disadvantages, because of the lack of data on anti-
IgE antibody during pregnancy.
To treat exacerbations, administer a SABA. If the
effects are insufficient, use oral medicine or injection
(steroids and intravenous infusion of aminophylline).
Oxygen inhalation is recommended to prevent fetal
hypoxemia. Complications, such as abortion and pre-
mature delivery, premature rupture of the mem-
branes, albuminuria, and eclampsia, are more com-
mon among patients with asthma. Certain congenital
disorders (malformation) are seen in 2% to 4% of nor-
mal pregnancies. These complications should be ex-
plained in detail before administration to obtain pa-
tient’s consent. It is more important to avoid exacer-
bation factors such as allergens and stress than to in-
troduce pharmacological treatment. In addition,
smoking, including passive smoking, has more seri-
ous consequences for the mother and fetus than any
other clinically used agents do. This must be ex-
plained to patients, their spouses, and people around
them to understand the necessity of smoking cessa-
tion.108
6.6. Comorbidity
6.6.1. Allergic rhinitis
Allergic rhinitis is divided into two major types: per-
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ennial allergic rhinitis and seasonal allergic rhinitis.
In Japan, about 40% of people have allergic rhinitis,
and the number of patients with seasonal allergic
rhinitis has increased recently. Allergic rhinitis is
“type I allergic reaction disease in nasal mucosa and
is characterized by 3 main symptoms including epi-
sodic and repeated sneezing, watery nasal discharge
and nasal congestion”. Asthma is commonly associ-
ated with allergic rhinitis. The lower respiratory tract
is connected to the bronchus and the upper respira-
tory tract including the nose and paranasal sinuses,
thereby influencing one another. Thus, a concept of
“one airway, one disease” has been proposed. It has
been reported that about 80% of asthmatic patients
have allergic rhinitis, and 10% to 20% of the patients
with allergic rhinitis also have bronchial asthma. A
nationwide Japanese study has revealed that 67.3% of
26,680 asthmatics have allergic rhinitis.109 Perennial
allergic rhinitis caused by house dust mite is thought
to be involved in the symptoms of asthma. Mean-
while, it has been reported that patients with seasonal
allergic rhinitis experience asthma exacerbations dur-
ing pollen allergy season.110 In asthmatic patients
with allergic rhinitis receiving nasal corticosteroids,
asthmatic symptoms are often improved. LTRA is
beneficial to allergic rhinitis as well as asthma. Aller-
gen immunotherapy (hyposensitization therapy) is ef-
fective and can be used as the first-line treatment for
allergic rhinitis. Even if patients are not completely
cured, about 70% of them can reduce the dose of
drugs for allergic rhinitis. Allergen immunotherapy is
reportedly effective not only for allergic rhinitis but
also for asthma control; however, the therapy should
not be used in severe asthma.111 It rarely causes an
asthma attack (11,000-2,000 injections) and, even
more rarely, a severe anaphylactic reaction (1
2,500,000 injection). After a subcutaneous injection,
patients should be observed at least for 30 min. Long-
term subcutaneous allergen immunotherapy (over 2
years) is required to bring effects. However, in some
patients, the therapy has no effects on rhinitis. Sublin-
gual allergen immunotherapy is also effective and
less invasive.
6.6.2. Sinusitis; otitis media
(1) Chronic sinusitis
The association of asthma with chronic sinusitis is
well-established. From 50% to 75% of asthmatic pa-
tients show abnormal findings in the paranasal si-
nuses on radiography. Chronic sinusitis is signifi-
cantly more common in patients with severe asthma
compared with those with mild asthma. The sinusitis
score assessed by computed tomography is worse in
asthmatics than in healthy subjects, and the score is
positively correlated with the rate of asthmatic com-
plications. Complication rate of nasal polyp is also
higher in patients with more severe asthma. About
90% of the patients with AIA have nasal polyp. Low-
dose macrolide therapy is effective for neutrophilic si-
nusitis and often improves asthma symptoms.
(2) Eosinophilic sinusitis; eosinophilic otitis me-
dia
Eosinophilic sinusitis is characterized by severe infil-
tration of eosinophils into the nasal mucosa and
polyp, and is resistant to surgical treatment and
macrolide therapy. Ethmoidal sinus is the main
pathological lesion and is complicated with the distur-
bances in the sense of smell. Eosinophilic sinusitis is
characterized by numerous polyps and severe eosino-
philic infiltration. It usually develops in adulthoods
and is considerably complicated with asthma. Eosino-
philic sinusitis sometimes induces otitis media, called
eosinophilic otitis media. Both diseases worsen the
QOL by impairing the sense of smell and hearing.
Only steroid treatment is effective in both diseases.
6.6.3. Churg-Strauss Syndrome (Eosinophilic
granulomatosis with polyangiitis)
(1) Definition
CSS is characterized by a history of asthma, increase
of eosinophil count in the blood and tissues, and mul-
tiple mononeuropathy and polyangiitis of many or-
gans. CSS was previously known as “allergic granulo-
matous angiitis”, but is now usually referred to as
“eosinophilic granulomatosis with polyangiitis”. CSS
is one of antineutrophil cytoplasmic antibody
(ANCA)-related systemic polyangiitis as well as
granulomatosis with polyangiitis (Wegener’s granulo-
matosis) and microscopic polyangiitis. The main
pathological lesions in these diseases are observed in
the microvessels of the arteriole and venula. Mi-
crovessels of the lungs and kidneys are often im-
paired. CSS is pathologically characterized by granu-
lomatous necrotic polyangiitis infiltrated with eosino-
phils and lymphocytes.
The mechanisms underlying the onset of CSS re-
main unknown.
(2) Epidemiology
The onset of CSS is generally observed in patients
older than 45 years. According to some Japanese re-
ports, the prevalence of CSS is about 0.2% in male and
0.5% in female patients with asthma.
(3) Typical disease progression
Disease progression in CSS is divided into three clini-
cal stages. In the first stage, patients develop eosino-
philic sinusitis with asthma and nasal polyp. In the
second stage, an increase in blood eosinophil count,
worsening of asthma control, and occasionally,
eosinophilic pneumonia are observed. In the third
stage, systemic polyangiitis develops. In general, sys-
temic polyangiitis occurs within several years after
the onset of asthma. Typical symptoms of CSS are fe-
ver, muscle pain, and body weight loss. More than
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90% of the patients have multiple mononeuropathy
and eosinophilia in the peripheral blood. Skin symp-
toms, cardiac disturbance, and ischemic bowel dis-
ease are observed in 50% of the patients. Eosinophilia
and elevated C-reactive protein, lactate dehydroge-
nase, and creatinine kinase levels are observed. Two-
third of the patients have elevated serum IgE levels,
positive conversion of rheumatoid factor, and in-
creased platelet count. A positive ratio of MPO to AN-
CAs is about 30% to 40% in patients with CSS.
(4) Atypical disease progression
Most patients with CSS show typical disease progres-
sion. However, less symptomatic patients or those
with fulminant progression of the disease are also re-
ported.
(5) Characteristic manifestations in asthma with
CSS
Asthma that precedes CSS usually develops in adult-
hood, and most of the patients with CSS have severe
disease with marked eosinophilia. Less than a half of
the patients are atopic before the onset of CSS. Al-
though patients with CSS usually have severe
asthma, airway hyperresponsiveness is mild before
the onset of CSS. When in remission after the devel-
opment of CSS, patients have fixed airflow limitation.
It has been reported that eosinophil count both in the
peripheral blood and sputum may predict relapse in
CSS.112 A pathological lesion of the upper airway is
similar to that in AIA, and about 70% to 80% of the pa-
tients with CSS show eosinophilic sinusitis and, occa-
sionally, eosinophilic otitis media.
(6) Diagnosis and treatment
A physician should carefully observe the clinical
course of severe asthma, especially in patients with
weak atopic eosinophilia, frequent eosinophilic pneu-
monia, or eosinophilic sinusitis. If patients have palsy,
muscle weakness or symptoms, the differential diag-
nosis of CSS should be made. In case of atypical CSS,
a pathological examination is required. The positive
rate of perinuclear antineutrophil cytoplasmic anti-
body (P-ANCA) is about 30% to 40% for the diagnosis
of CSS; therefore, CSS cannot be excluded on the ba-
sis of negative P-ANCA test results. Early diagnosis
and treatment are important because polyangiitis may
progress rapidly. Treatment for CSS after a clinical di-
agnosis should be started without a pathological ex-
amination. It is important to record any digestive dis-
orders and cardiac diseases because they determine
prognosis. The treatment of CSS essentially involves
systemic steroids. In patients with severe disease,
those with cardiac disease, or steroid-resistant pa-
tients, cyclophosphamide is concomitantly used with
systemic steroids. High dose immunoglobulin is in-
travenously administered in treatment-resistant pa-
tients with nerve or cardiac disorders.
6.6.4. Allergic bronchopulmonary mycosis
(1) Definition
Because fungus repeatedly infects the airways of the
sensitized asthmatic patients with specific IgE against
the antigen of fungus in ABPM, not only IgE but also
specific IgG is produced. Consequently, both type I
and III allergic reactions occur in the airways and re-
sult in the destruction of the airway walls. Central
bronchiectasis and thickening of the airway walls oc-
cur in a relatively early stage of the disease. Destruc-
tion of the airway walls causes chronic infection, and
patients with ABPM finally suffer from chronic respi-
ratory failure. When a specific antigen is Aspergillus
fumigatus, ABPM is called “allergic bronchopulmon-
ary aspergillosis”. Instead of Aspergillus fumigatus, As-
pergillus niger or Aspergillus oryzae can induce ABPM.
Since Aspergillus oryzae is used for brewing miso and
the soy sauce, ABPM is involved in occupational
asthma. Other fungi such as Penicillium, Cladospo-
rium, and Candidamay be responsible for ABPM.
(2) Pathogenesis
Injured airway epithelial cells induced by asthma or
cystic fibrosis lead to ABPM. It has been reported
that HLA-DRB1 genes predispose to ABPM because
Th2 reaction against Aspergillus easily occurs in pa-
tients with this genetic background.113 After expo-
sure to Aspergillus, it persistently infects the lower
airway walls. After Th2 cells are activated, strong Th2
allergic reaction against Aspergillus occurs. Then,
greater amounts of IgE and IgG antibodies against
Aspergillus are produced through the production of
IL-5 and granulocyte macrophage colony-stimulating
factor (GM-CSF). Aspergillus secretes various types
of proteases that cause tissue destruction and dys-
function of the airway epithelial cells. Then, not only
eosinophilic but also neutrophilic inflammation is in-
duced by IL-6 and IL-8 released from the airway epi-
thelial cells and macrophages. Viscous sputum is re-
tained in the central airways and mucoid impaction is
formed. Subsequently, atelectasis and lung infiltra-
tion are formed.
(3) Diagnosis
Early diagnosis is important because any delay re-
sults in chronic airway infection and respiratory fail-
ure. The diagnostic criteria for ABPA include asthma,
eosinophilia of the peripheral blood, positive results
of immediate allergic reaction test against Aspergillus,
positivity for precipitation antibodies against Aspergil-
lus, elevated serum IgE levels, a history of lung infil-
tration, and central bronchiectasis. If all criteria are
fulfilled, the diagnosis is considered as “confirmed”; if
6 of the 7 criteria are fulfilled, the diagnosis is consid-
ered as “almost confirmed”.114 However, early diag-
nosis or atypical case of ABPA does not match these
criteria, and, recently, the criteria have been modi-
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fied.115 Greenberger et al. proposed new criteria for
early diagnosis in patients with or without central
bronchiectasis (ABPA-bronchiectasis and ABPA-
seropositive, respectively). When ABPA is diagnosed,
patients with positive skin test results or patients
positive for specific IgE are thought to be susceptible
to ABPA. Particularly, patients with high serum IgE
levels, precipitation antibodies or specific antibodies
against Aspergillus should be investigated. If the test
results are positive, patients are diagnosed as ABPA-
seropositive. Central bronchiectasis is diagnosed by
chest computed tomography.
(4) Morbidity
About 2% to 3% of the patients with asthma are re-
ported to be ABPA-seropositive in Japan. About half
of them are diagnosed as ABPA-bronchiectasis.
(5) Treatment
Early diagnosis and treatment are important, and
treatment should be started at the ABPA-seropositive
stage. Environmental measures seem to be clinically
effective for ABPA. In typical ABPA, lung infiltration
reoccurs, and, consequently, the progression of cen-
tral bronchiectasis and airway wall thickening are ob-
served. During acute exacerbations, systemic ster-
oids should be administered to improve lung infiltra-
tion and prevent irreversible airway destruction. In
general, more than medium doses of steroid (predon-
isolone, 0.5 mgkg) are administered. A steroid dose
should be reduced over several weeks. During the
chronic stage, ICSs are used along with long-term
asthma treatment; however, in some cases, low doses
of oral steroid are needed. To reduce the amount of
Aspergillus, it is important to undertake environ-
mental measures at home and at the office. For long-
term management, the measuring of total serum IgE
levels and chest radiography need to be routinely per-
formed. A concomitant use of itraconazole is effective
in the prevention of relapse, lung infiltration, reduc-
tion in serum IgE levels and sputum eosinophil
count. The blood levels of itraconazole should be
monitored because of the risk of side effects.
6.6.5. Heart failure
Symptoms of heart failure mimic those of asthma and
a differential diagnosis is often difficult. The definition
of acute heart failure is as follows: “Heart failure is
caused by pump dysfunction induced by cardiac or-
ganic andor functional disorder. Heart failure is also
characterized by symptoms and signs induced by ele-
vation of ventricular diastolic pressure and loss of
perfusion in main vital organs.” Heart failure is classi-
fied as acute decompensated heart failure, hyperten-
sive acute heart failure, acute cardiac pulmonary
edema, cardiac shock, high-output heart failure, and
acute right ventricular failure. Symptoms of heart fail-
ure are dyspnea on exertion, palpitation and fatigue
induced by the elevation of the left atrial pressure,
and lung congestion at an early stage of left ventricu-
lar heart failure. In addition, patients with heart fail-
ure are characterized by anorexia, constipation, nau-
sea, vomiting, feeling of fullness in the abdomen, leg
edema, and body weight gain due to systemic con-
gestion. In the later stages, torpor, oliguria, cyanosis,
limb coldness, decline in memory function, distur-
bances of consciousness are observed as symptoms
of congestive heart failure. In severe cases, episodic
dyspnea at night and orthopnea develop. A prospec-
tive study of patients with heart failure showed the
following symptoms during hospitalization: episodic
dyspnea at night (55.4% of the patients), orthopnea
(68.5%), coarse crackles (77.6%), gallop rhythm
(40.5%), juggler venous distension (61.3%), leg edema
(67.7%), and limb coldness (23.3%). If the above signs
and symptoms are observed, there is a high probabil-
ity of heart failure. In the case of heart failure, pulmo-
nary vasodilation and heart enlargement are ob-
served on a chest radiograph, in addition to other
common signs such as Kerley lines, ground-glass
opacity, butterfly pattern, or bat’s wing pattern. When
heart failure is suspected, the measurement of brain
natriuretic peptide levels and serum N-terminal pro-
B-type natriuretic peptide levels, echocardiogram,
and Swan-Ganz catheter are useful tools that allow to
diagnose heart failure and evaluate its possible
causes and severity. Patients with heart failure may
show obstructive lesions on spirometry as well as air-
way hyperresponsiveness. Systemic steroids and β2-
stimulant may worsen heart failure. Anticholinergic
agents improve dyspnea and pulmonary function in
patients with heart failure. Theophylline and amino-
phylline improve cardiac stress and pulmonary
edema and are approved for use and covered by in-
surance in Japan. However, their blood levels should
be carefully monitored because of low drug clear-
ance. β-blockers are effective for the treatment of
heart failure. Highly selective β1-blockers are safe for
asthmatic patients, and may be carefully administered
to asthmatic patients with heart failure.
6.6.6. Gastroesophageal reflux disease
GERD is an esophageal disease characterized by
heartburn. It is caused by the reflux of the gastric
contents from the stomach into the esophagus, and
induces various clinical symptoms and complications.
GERD often causes chronic cough, throat pain, and
noncardiogenic chest pain and sometimes induces
asthma. Less than 5% of the Asian people are reported
to have GERD, and the prevalence is lower than that
in Western countries. About 6.6% to 37.6% of the Japa-
nese people have GERD and the prevalence has been
observed to increase recently. The prevalence of
GERD in asthmatic patients is about 45% to 71% and is
higher than that in the general population. Asthmatic
patients with GERD have more asthmatic symptoms
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than those without GERD and receive more oral ster-
oids to relieve symptoms. A previous report showed
that bronchoconstriction induced by asthma en-
hanced gastroesophageal reflux.116 Moreover, other
reports demonstrated that the clearance of gastric
acid was reduced in patients with asthma, and a de-
crease of esophageal pH induced airway hyperre-
sponsiveness and a decline in pulmonary function.117
Proton-pump inhibitors are expected to improve the
pulmonary function, QOL, and symptoms in asth-
matic patients with GERD, while they are unable to
improve asthma control or pulmonary function in un-
controlled asthmatic patients without GERD. If the
symptoms are not improved by proton-pump inhibi-
tors, a surgery for GERD is sometimes effective.
6.7. Occupational Asthma
Occupational asthma is defined as “asthma induced
by exposure to a specific occupation-related sub-
stance in the office”. Asthma control is often exacer-
bated by environmental factors found in the office.
Recently, asthma exacerbated by work-related factors
has been termed “work-related asthma”. The inci-
dence of occupational asthma in Japan is unknown,
but about 9% to 15% of asthmatic patients in countries
other than Japan have occupational asthma.
6.7.1. Causative substance
Various types of substances can cause asthma. They
are classified into irritant substances (chlorine, acetic
acid, smoke, and others) and sensitizing substances.
Sensitizing substances are classified into high-
molecular-weight substances, such as protein, and
low-molecular-weight substances, such as chemicals.
Occupational asthma is classified into sensitized and
irritant-induced. Reactive airway dysfunction syn-
drome is classified as induced occupational asthma.
Most of the high-molecular-weight substances and
some of the low-molecular-weight substances (plati-
num salt, acid phthalic anhydride, and some others)
induce sensitized occupational asthma. In this type of
asthma, specific IgE against the causative substance
is sometimes detected; therefore, it is expected that
IgE may be involved in the development of asthma.
Atopy and smoking are risk factors for sensitized oc-
cupational asthma.
6.7.2. Clinical presentation and diagnosis
A diagnosis of work-related asthma is mainly based
on a medical history. It is necessary to evaluate
whether patients are exposed to the causative sub-
stances in the office within 24 hours, whether asthma
symptoms are improved during holidays or when out
of office, or whether allergic rhinitis or allergic con-
junctivitis is exaggerated in the office. It is difficult to
diagnose sensitized occupational asthma only by
medical interview. Therefore, it is also necessary to
monitor PEF 4 times a day (at least for 2 weeks in the
office and 2 weeks out of office). It is also useful to
evaluate airway hyperresponsiveness and measure
sputum eosinophil count in or out of office and to per-
form a skin prick test or detect specific IgE. A chal-
lenge test is also a useful diagnostic tool. Detection of
specific IgE may be useful but the availability of com-
mercially available detection kits or drugs is limited.
To diagnose irritant-induced occupational asthma,
medical interview is the most important when it re-
veals that asthma symptoms are induced within 24
hours after exposure to an occupation-related irritant.
6.7.3. Treatment
Treatment in occupational asthma involves various
measures to ensure reduction of the causative sub-
stances in the office. Continuous exposure aggravates
symptoms and worsens pulmonary function. Avoid-
ance of exposure is insufficient to improve symptoms.
In occupational asthma induced by latex, the use of
nonlatex gloves is recommended. Pharmacological
treatment is generally similar to the treatment of
asthma. ICSs are effective in sensitized occupational
asthma in addition to the avoidance of exposure to
causative substances. After a causative antigen has
been identified, if patients are unable to avoid expo-
sure, allergen immunotherapy may be effective. A re-
cent report has shown that monoclonal anti-IgE anti-
body was effective in a patient with severe occupa-
tional asthma who worked at a bakery.118 If patients
are unable to avoid exposure to causative substances,
the change of the occupation or workplace may be in-
evitable.
6.7.4. Precautions
As primary precaution, environmental measures in-
cluding clearance or reduction of the causative sub-
stances at the office are important. Improvements in
work methods and in ventilation and cleaning of the
office are necessary. If needed, workers should wear
a mask and use protective equipment. As secondary
precaution, medical surveillance is required to avoid
exacerbations when sensitized occupational asthma
occurs at the office. Patient questionnaires, spirome-
try, measurement of serum specific IgE levels, and
skin prick test should be repeated regularly.
6.8. Surgery
Although numerous studies have shown that patients
with asthma often experience respiratory complica-
tions such as bronchoconstriction or barotrauma dur-
ing the perioperative period, a previous report
showed that only 1.7% of asthmatic patients who un-
derwent a surgery had bronchoconstriction during
the perioperative period.119 In addition, respiratory
complications do not cause pneumothorax, pneumo-
nia, or death. The incidence of respiratory complica-
tions is associated with the severity of asthma, type of
surgery (surgeries of the chest and upper abdomen
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carry a higher risk), or the method of anesthesia (in-
tubation and sympathetic nerve block carry a higher
risk). Before surgery, the severity of asthma should
be evaluated on the basis of clinical history, symp-
toms, physical examination, and pulmonary function,
and the method of anesthesia should be determined.
To additionally treat asthma, the condition of patients
should be evaluated at least several days prior to sur-
gery.
6.8.1. Management before surgery
(1) Evaluation of the severity of asthma
The severity and control of asthma should be accu-
rately evaluated in terms of the clinical history, symp-
toms, physical examination, pulmonary function, PEF
values, and arterial blood gas analysis. A physician
needs to assess the current treatment, use of asthma
medications, history of surgeries, and allergy to latex.
A history of allergy to NASIDs after the onset of
asthma should be confirmed because it affects the
choice of analgesic agents.
(2) Timing of surgery
Surgery should be performed during the stable pe-
riod of asthma without exacerbations. If asthma is
poorly controlled and the surgery can be postponed,
additional treatment should be administered until
good control and normal pulmonary function are
achieved. If an emergency operation is required in
unstable patients, asthma should be controlled with
systemic steroid during the perioperative period.
(3) Pharmacological treatment
If the current treatment is sufficient to maintain good
control of asthma, it should be continued. If the con-
dition is unstable, additional treatment should be con-
sidered. ICSs should be given if the patient is steroid-
naïve without any symptoms, and there is enough
time to administer an ICS. If the condition is unstable,
FEV1 is less than 80%, or PEF values against personal
best values, treatment with oral corticosteroids (pre-
donisolone, 0.5 mgkgday, for 3-7 days) should be
considered. If there is not much time left before the
surgery or oral steroids cannot be administered, an
intravenous administration of corticosteroids should
be considered. There is no evidence as to the dura-
tion of treatment and required steroid doses. If pa-
tients continue to take oral steroids for more than 6
months, steroid cover should be considered during
the perioperative period. Although hydrocortisone at
a dose of 100 mgday is generally administered day
before the surgery, and 100 mg every 8 hours on the
day of surgery, the doses and intervals in treatment
should be reviewed in the future. If the patient takes
a high dose of ICSs and will not be able to inhale the
drug during the perioperative period, an intravenous
administration of a systemic steroid should be consid-
ered. As soon as the patient is able to inhale the drug
again, a systemic steroid should be switched to an
ICS.
6.8.2. Anesthesia
(1) Local and spinal anesthesia
Local or spinal anesthesia is performed in small sur-
gery or peripheral injury without any effect on the
respiratory system. Sympathetic nerve blockade by
high spinal and epidural anesthesia may induce bron-
choconstriction and asthma attack. In patients with a
history of allergy to local anesthetic agents, a skin
prick test or intradermal challenge test should be per-
formed. Diphenhydramine is reportedly used instead
of local anesthetic agents.
(2) General anesthesia
Although general anesthesia can be safely performed
in proper respiratory-care setting, intubation may in-
duce bronchoconstriction in asthmatic patients. Anes-
thetic agents with bronchodilatory action are used to
induce and maintain anesthesia. Intubation should be
performed after sufficient anesthetic depth has been
achieved. Humidification of the inhaled air, preven-
tion of dehydration, and intravenous lidocaine injec-
tion prior to intubation should be considered.
(3) Anesthetic agents
Of inhaled anesthetics, dinitrogen monoxide, isoflu-
rane, and sevoflurane are generally used. Among
them, sevoflurane is the first-choice drug for asth-
matic patients. Aminophylline and β2-stimulants may
induce ventricular arrhythmia under anesthesia with
halothane; therefore, isoflurane or sevoflurane should
be used. Of intravenous anesthetics, thiopental, thia-
mylal, ketamine, propofol, midazolam, remifentanil,
and fentanyl are used. The use of thiopental and thia-
mylal is contraindicated in asthmatic patients owing
to bronchoconstrictive action of these drugs. Al-
though propofol has bronchodilatory action and is
used in inducing anesthesia, it should be adminis-
tered with caution because of possible bronchial
spasm.
6.8.3. Treatment of asthma attack during surgery
When asthma attack occurs during surgery, inhaled
β2-stimulant, intravenous drip infusion of corticoster-
oid (hydrocortisone, methylprednisolone) and amino-
phylline, subcutaneous injection of adrenaline (0.1%),
and inhalation of oxygen are recommended.
6.8.4. Postoperative management
After awakening, the patient should be extubated. Be-
cause asthma attack is often induced by various stim-
uli after the surgery, it is important to monitor the pa-
tient carefully. When wheezing continues after the
surgery, β2-stimulant is inhaled before extubation and
sufficient dose of a systemic steroid should be admin-
istered. If AIA cannot be excluded, NSAIDs must not
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be used. Morphine hydrochloride is contraindicated
because it may induce bronchoconstriction.
6.9. Cough-Variant Asthma
Cough-variant asthma (CVA) is characterized only by
chronic dry cough without wheezing, attack of dysp-
nea, and abnormal pulmonary function. If cough con-
tinues for more than 8 weeks, it is called chronic
cough. CVA is the major cause of chronic cough. In
Japan, chronic cough is caused by CVA (36% of the
cases), atopic cough (16%-29%), sinobronchial syn-
drome (16%-17%), postinfectious cough (2%), and
GERD (2%).120 Cough variant asthma is distinguished
from asthma by the lack of wheezing. CVA belongs to
the subgroup of asthma or intermediate asthma and
is similar to asthma in the following aspects: (i) air-
way hyperresponsiveness is mild (intermediate be-
tween patients with mild asthma and healthy individu-
als)121; (ii) cough sensitivity is within the normal
range; (iii) atopic state is common; (iv) eosinophils
are noted in sputum or induced sputum; (v) eosino-
philic infiltration is noted in the bronchial mucosa;
(vi) eosinophils are increased in the bronchoalveolar
lavage fluid; (vii) fraction of exhaled nitric oxide
(FeNO) is increased; and (viii) inhaled or oral corti-
costeroids are effective. Bronchodilators, including β
2-agonists, are effective for cough. CVA is not usually
accompanied by sputum, is more severe at bedtime,
during the night and early morning, and is induced
by cold and warm air, passive smoking, conversation,
exercise, alcohol, mental stress, and others. About
30% of the patients with CVA develop wheezing
asthma. Since cough can be prevented with an ICS,
long-term management with an ICS is recommended.
Atopic cough is similar to “non-asthmatic eosino-
philic bronchitis” in Europe and the United States.122
Atopic cough is somewhat similar to CVA in clinical
symptoms, and has the following features: (i) pres-
ence of the atopic state; (ii) bronchodilators such as
β2-agonists are ineffective; (iii) there is no airway hy-
perresponsiveness; (iv) cough sensitivity is in-
creased; (v) H1-antagonists and steroids are effective;
and (vi) asthma does not develop. Long-term man-
agement is unnecessary. In addition, unlike in CVA,
FeNO levels do not increase. Other important dis-
eases, differentiated from chronic nonproductive
cough, include cough caused by postnasal drip, gas-
troesophageal reflux, or angiotensin-converting en-
zyme inhibitors.
6.10. Aspects of Psychosomatic Medicine
Psychosomatic factors have long been reported to be
associated with asthma. As early as in the years 400
to 300 BC, Hippocrates postulated that feeling of an-
ger or animosity could be involved in asthma attack.
Many reports have demonstrated that asthma control
is strongly affected by psychosomatic factors. It has
been reported that psychosomatic and social back-
ground as well as family lifestyle affect the develop-
ment, exacerbations, and management of asthma.
6.10.1. Psychosomatic background
(1) Stress and asthma
Asthma control is affected by stress. Particularly, de-
pression or panic disorder is observed in patients
with mild asthma who are treated by general physi-
cians. Associations between depressive tendencies
and hospitalization rates and between panic disorder
and emergency room visits have been reported.123 To
reduce healthcare cost and severity of asthma, early
diagnosis and treatment of depression, panic disor-
der, and other stress-related conditions are needed.
(2) Current adherence rates
Adherence to treatment is important in asthma con-
trol. According to a previous study in pediatric pa-
tients, although the mean rate of ICS use recorded by
patients in their asthma diaries was 94.5%, the actual
mean rate was 58.4% as measured by the electronic
counter in inhaler devices. Similar results have been
reported for adult asthma.
(3) Consequences of severe asthma or death
from asthma
Patients who had a near-fatal attack are characterized
by large fluctuations in PEF values, poor adherence
to treatment, and poor asthma control compared with
patients who did not have a near-fatal attack. More-
over, it has been reported that these patients have
limited capacity to adapt to treatment and psychoso-
matic disorders that negatively affect asthma manage-
ment.
6.10.2. Diagnosis of asthma in psychosomatic
medicine
(1) Development, relapse, exacerbation, and per-
sistence of asthma due to psychosomatic stress
When psychosomatic stress is an exacerbating or
triggering factor, changes in lifestyle and various
events (childbirth, marriage, divorce, moving house,
losing a job, job change, hospital admission, death of
a close relative) or stresses of daily life (at home,
work, school, etc.) are often observed prior to the de-
velopment or relapse of asthma. There is a close rela-
tionship between the psychological condition (anxi-
ety, tension, anger, depression, etc.) and asthma
symptoms.
(2) Social adaptation problems associated with
asthma
Asthma is a chronic disease with frequent exacerba-
tions and relapses during its clinical history. The dis-
ease is associated with considerable physiological,
psychological, temporal, and economic burden.
Asthma sometimes induces psychological distress
and negatively affects social and professional life of
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the patients, often resulting in the development of
psychosomatic disease. This, in turn, is associated
with sleep disorders, problems in personal relations,
social isolation, worse performance at school or work,
depression, and anxiety.
(3) Nonadherence to asthma treatment
Psychosomatic factors may lead to poor adherence to
asthma treatment. Consequently, they adversely af-
fect the course and outcomes of treatment. More-
over, they cause irrational anxiety, fear, and the sense
of helplessness in controlling the disease, as a result
of which, patients often develop distrust in physicians
or medical care. This leads to treatment failure or
considerable delays as well as inadequate self-
management. Patients with maladaptation to stress
tend to have more severe and refractory asthma.
Sometimes, it is impossible to stop systemic steroid
treatment in these patients, which can even lead to
death. Symptoms of asthma are closely related with
recognition of patients’ own treatment and manage-
ment, so questionnaires such as the Perceived Con-
trol Asthma Questionnaire have been developed for
evaluating the state of recognition of medication.
6.10.3. Psychophysiological treatment
Counseling is the principal method in psychophysi-
ological treatment. Providing acceptance, sympathy,
and support to patients helps them express emotions,
recognize the relationship between the mind and
body, and manifest emotional problems. In addition,
pharmacotherapy, autogenic training, cognitive be-
havioral therapy, family therapy, and fasting therapy
are attempted. Diary writing alone has been reported
to improve the symptoms of asthma in psychosomatic
patients.124 If asthmatic patients with anxiety disorder
or mood disorders often suffer from exacerbated
asthma, antianxiety or antidepressant agents may be
effective in the management of an asthma attack in
addition to regular asthma drugs. If the actual stress
is more causative than some aspects of the patient’s
personality, autogenic training is useful. For personal-
ity issues, a physician should consult a specialist in
psychosomatic medicine, or a team approach with
psychotherapist and specialist is recommended.
6.11. Immunization
6.11.1. Guidelines on immunization
(1) Perspective of the Japanese Society of Pedi-
atric Allergy and Clinical Immunology
The guidelines on immunization were revised in
2012; they present the perspective of the Japanese So-
ciety of Pediatric Allergy and Clinical Immunology.
(2) Constituents of vaccine relating to allergy
Constituents of vaccine that are related to allergy in-
clude egg-related antigen, antiseptic agents or addi-
tive substances, medium or antimicrobial agents, and
vaccine antigens. Latex allergy may sometimes be
problematic (yellow fever vaccine).
6.11.2. Precautions in immunization in asthmatic
patients
In the USA, immunization is recommended for asth-
matic patients except for specific cases since asth-
matic patients tend to exaggerate serious symptoms
and attack with respiratory infection. In general, im-
munization of live viral vaccine can be used in asth-
matic patients with low-to-intermediate doses of sys-
temic steroids (lower than 20 mgday). However, live
viral vaccine should be discontinued a month later in
patients receiving 2 mgkgday or more than 20 mg
day of prednisolone over 2 weeks.
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